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Abstract 
Since the discovery of antibiotics, an ongoing race commenced between 
society’s ability to develop drugs and resistant bacteria.  The combat has led to many 
drug discoveries, but it has also led to different mechanisms of the pathogens to evade 
cell death.  One major means of bacterial resistance is the association of membrane 
proteins to expel substrates from within the cell and out into the extracellular space. 
Some protein complexes are able to oust various drugs irrespective of structure or 
function of the antimicrobial; these are the multidrug resistance (MDR) efflux pumps.  
In the Gram-negative bacteria, these complexes are made up of an inner membrane 
transport protein (IMP), a periplasmic adapter protein (PAP) also commonly known as 
the membrane fusion protein (MFP), and an outer membrane protein (OMP).  This 
assembled conduit acts as a canal to channel substrates from within the cytoplasm – 
substrates are repositioned outside the nearly impenetrable outer barrier. 
 Escherichia coli AcrAΒ-TolC is a constitutively expressed MDR pump. As one 
of the most studied systems, all three proteins have been crystalized, allowing for better 
understanding of the protein structures and properties.  Many biochemical and structural 
experiments have aided predictions about protein-protein interactions and mechanisms 
of function of this protein complex. However, the homo-identity of all proteins in 
complex limits the isolation of roles and mechanistic characterization. The recently 
discovered TriABC-OpmH of Pseudomonas aeruginosa uniquely expresses two MFPs 
(TriA and TriB) and serves as a model system to study the assembly of efflux pumps 
and the function of MFPs in complex.  In this study, we used the transporter protein 
AcrB to characterize kinetic parameters of efflux pump inhibitors (EPIs) provided by 
xv 
Basilea Pharmaceutica.  Next, we used the TriABC complex as the means of studying 
the MFP-OMP amino acid interfaces.  We investigated the role and assembly of TriA/B 
with the partnering OMP.  We confirmed that MFPs stabilize interactions with the outer 
membrane channel protein, and we also assigned MFPs the role of opening the channel 
protein.  Results isolated the role of each MFP within the functional dimeric complex.  
Additionally, we present low-resolution structures of TriABC showing different 
conformations of the TriAB MFPs.  In vivo proteolysis experiments validate the 
structural findings, while presenting an OMP-dependent conformational change within 
one MFP.  Together, this study provides new insight into the mechanism of MDR efflux 
complex, inspiring innovative drug targets and new drug designs to reciprocate and 




In recent years, a major threat to public health has stemmed from bacterial 
infections.  Many antimicrobials have been discovered or synthetized over the decades 
to address infections caused by Gram-negative and Gram-positive bacteria alike.  These 
therapeutics are categorized into different classes, grouping them by the target of action 
within the cell 10.  Despite the variety of drugs and broad spectrum activities of some, 
they are proving futile in the treatment of infections due to the cell’s ability to acquire 
resistance to the treatments.   
Bacterial cells have gained resistance to drugs by intrinsically mutating the drug 
binding site; degrading or modifying the antibiotic when it enters the cell; or preventing 
the entrance or diffusion of drugs across the cell wall 5, 10, 11.  If any drug should bypass 
these mechanisms of resistance, there are proteins within the cell membranes that allow 
extrusion of substrates across the inner and outer membranes (Figure I.0.1).  Such 
resistance has led to increased dosages, as well as the use of drug cocktails to enable 
effective treatment of infections. However, cells continue to gain resistance to most 
administered therapeutics, irrespective of the structural or functional differences. 
Multidrug resistance (MDR) bacteria include Gram-negative pathogens like 
Pseudomonas aeruginosa and Klebsiella pneumoniae, etc.  It is imperative that new 
drugs are designed that have different targets and binding sites, more than has been 
done before, to help combat infections by these microbes. 
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I.1 Multidrug Efflux 
 One major means of resistance is the use of multidrug efflux (MDE) pumps.  
Granted the components of MDEs are the same – an outer membrane channel protein, 
an inner membrane transporter protein, and periplasmic adapter proteins – the substrate 
specificities vary. These complexes are also distinguished by source of energy for pump 
functionality.  ATP Binding Cassette (ABC) type transporters use the hydrolysis of 
ATP molecules as the energy needed for activation 10.  Secondary transporters of the 
Major Facilitator Superfamily (MFS) 12, Small Multidrug Resistance (SMR) 13, 
Multidrug and Toxic Compounds Extrusion (MATE) 14, Resistance Nodulation Cell 
Division (RND) 15, and the recently discovered Proteobacterial Antimicrobial 
Figure I.0.1 Mechanisms of Bacterial Resistance 
A. Cells modify intended target of the drug substrate, evading cell death.  B. 
Intrinsic enzymes are produces to alter the drug.  Drug may either be modified or 
degraded. C. Bacteria can change the cell wall composition to reduce diffusion or 
transport across the outer shell.  D. Intrinsically expressed proteins of the cell 
membrane (and cell wall, in Gram-negative bacteria) actively expel drug substrate 
out of the cell and into the extracellular space.5 
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Compound Efflux (PACE) 16 families use either the transport of ions such as Na+ or the 
proton motive force (PMF) to allow transport across the cell’s membranes. 
MDEs are composed of a transporter protein that is located in the inner 
membrane (IMP) – this uses energy to transport substrates out of the periplasm and 
cytoplasm; an outer membrane protein (OMP) acts as the channel through which 
molecules are expelled back outside the cell; and a flexible periplasmic protein (MFP) 
helps anchor and bridge the two proteins of either membrane 7, 10, 17.  In Gram-positive 
bacteria, where there is no need for an OMP, the inner membrane transporter allows 
substrates to cross the peptidoglycan layer and out into the extracellular space.  In some 
instances MFPs are present, as would be seen in Gram-negative bacteria 7.  
Pseudomonas aeruginosa is an opportunistic, Gram-negative pathogen that is 
notorious for its resistance to most antiseptics.  Pseudomonas aeruginosa has more than 




I.1.1 Membrane Fusion Proteins (MFPs) 
 The periplasmic adapter protein is a sickle-shaped protein. Due to lipid-
modification of the N-terminus cysteine or a transmembrane segment, MFPs are 
anchored to the inner membrane 9. In studies where the N-terminus cysteine is replaced 
or truncated, the protein is more mobile 9, 19, 20.  MFPs fold in symmetry, where all four 
domains are formed by amino acid residues located in the N- and c-terminal halves of 
the protein sequence (Figure I.0.2A). In the middle of the two-fold symmetry is the α-
helical domain, followed by the lipoyl and β-barrel domains; lastly, the protein folds 
into the membrane proximal domain (Figure I.0.2B).  The anti-parallel helices of the α-
helical domain has been found to vary in length from protein to protein, dependent on 
the species (Figure I.0.2C).  The α-helical, coiled coil domain has been shown to 
assemble and align along the surfaces of OMPs to allow a stabilizing and functional 
Figure I.0.2 Structure and Folding of Membrane Fusion Proteins (MFPs) 
A. Linear representation of the membrane fusion proteins showing the distribution of 
the four domains (purple – transmembrane segment/signal peptide, red – membrane 
proximal domain, yellow – β-barrel domain, green – lipoyl domain, and blue – α-helical 
hairpin domain) in the N- and C-terminus.  B. Crystal structure of MexA (PDB code: 
2V4D).  The domains of the protein are highlighted in colors corresponding to the linear 
diagram.  C. Crystal structures of various MFPs depicting the variation in protein 
structures, especially at the α-helical domain. (Adopted from 7 and modified 9) 
 
5 
complex 21.  Transitioning into the lipoyl domain, the protein folds are made of β-
strands.  This domain, though its functional role has yet to be elucidated, is thought to 
also contribute to the stabilizing of an MFP-OMP complex.  As the name implies, the β-
barrel is made up of anti-parallel β-strands, but it also includes one α-helix.  The fourth 
domain, the membrane proximal (MP) domain, follows the design of the previous 
domain.  Made up of β-strands and one α-helix, the MP domain is the most flexible 
region due to the nature of the linker region between the two domains.  The extent of 
this flexibility is evident in available crystal structures, where some lack the fourth 
domain 22.  
 Studies with various MFPs, including E. coli AcrA, have shed light on the role 
of the domains as well as interactions needed within a functional complex.  
Crosslinking studies mapped amino acid sites on MexA and AcrA to find binding sites 
to their partnering IMP and OMP 23, 24.  These studies showed that the β-barrel and MP 
domains interact with the IMP while the α-helices of MFPs interact with the OMP.  
SPR studies determined kinetic parameters of AcrA, EmrA, and MacA interactions with 
the universal channel, TolC 25.  Along with others studies, findings from Tikhonova et 
al. (2009) present the importance of the oligomeric state of MFPs within complex.  The 
existing evidence shows that MFPs function in a trimer of dimers, forming hexameric 
barrels surrounding the OMF.  Despite all the findings, there is much that remains to be 
learned about these flexible periplasmic proteins. 
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I.1.2 Outer Membrane Proteins (OMPs) 
Localized in the bacterial cell wall, channel proteins of efflux pumps have been 
characterized as the Outer Membrane Factor (OMF) family 26.  The first of its family to 
be crystalized, E. coli TolC revealed a unique protein structure 27.  Since then, homologs 
have been found to model this protein folding 21, 28-30.  The specificity of an OMF to a 
transporter-MFP pair is based on interactions with the MFP. However, some OMFs, 
like the E. coli TolC protein, are promiscuous – TolC has been shown to assemble in 
many efflux pump complexes 31-33. Thus, the basis of OMF recognition and specificity 
is still unclear. 
TolC extends from the extracellular space, spans the outer membrane and 
continues well into the periplasmic space.  This 140 Å long, channel-like protein is 
made up of a 12-stranded β-barrel and α-helical domain, and a mixed α/β-domain (also 
referred to as the equatorial domain) (Figure I.0.3A).  Like other OMPs, the TolC β-
barrel is a trimer embedded in the membrane; however, TolC exists as a homotrimer – 
each protomer contributes four β-strands.  The right-handed β-strands of the barrel 
render TolC wide open while the lack of inward-folded extracellular loops makes the 
protein accessible to large volumes of solvent (Figure I.0.3C).  At the periplasmic ends 
of the β-strands, proline-containing linkers initiate the change of orientation of the coil-
coiled α-domain to make them left-twisted helices.  The α-domain is made up of two 
long helices that span the nearly 100 Å into the periplasm and four shorter helices that 
stack up to make two long, pseudo-continuous helices that also span the length of the 
domain.  At the interface of the short helices are strands and helices (of α/β structure 
mixture) that attain their fold via hydrogen bonding and van der Waals interactions with 
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side chains (Figure I.0.3B).  Although there exists pseudosymmetry (in the α-domain) 
as two sets of coiled coils share similar sequences and interhelical interactions, one pair 
is more angularly inclined – 20° – towards the core of the protein.  The dense packing 
of the three curved sets of coiled coils has been speculated to be the reason for the 
periplasmic opening of TolC exhibiting a “closed” conformation (Figure I.0.3D) 27, 34-36. 
The periplasmic aperture of OMFs differs from protein to protein.  Some are in a closed 
conformation, like in TolC and CusC, but others still are left ajar, as is found in the 
MtrE protein structure 30.  The closed conformation of the TolC aperture is held closed 
by salt bridge interactions between the residues Thr 152, Asp 153, Tyr 362, and Arg 
367, as well as a second bottleneck composed of a network of aspartic acid residues 
(Asp 374) of the three protomers 37.  These closures prevent leakage across the protein 
channel.  Regardless, the cavity of TolC is one of the largest known protein structures, 
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holding about 43000 Å3 of solvent; it is capable of allowing passage of particles as large 
as 160 kDa.   
OMFs get help from the assembled trimer of dimeric MFPs around the channel 
protein to prevent leakage of substrates into the periplasm or diffusion from the external 
media 7, 9.  MFPs are also key in the opening of the outer membrane channel, by the 
disruption of salt bridges9. However, the mechanism of opening is dependent on the 
transporter protein, which relays conformational changes to the MFP in order to open 
the OMF. Molecular details of the mechanism of channel opening is yet to be 
elucidated. 
In addition to drug substrates, OMPs are also involved in the secretion of metals, 
as well as ions and other proteins across the outer membrane barrier. One such case is 
Figure I.0.3 Crystal Structure of the Outer Membrane Factor TolC 
A. The homotrimeric, universal outer membrane channel (PDB code: 1EK9). B. 
Blueprint diagram of the architecture of OMFs. (Dark blue – the equatorial region, blue 
– α-helices of the protruding barrel domain, and light blue – β-strands of the barrel 
spanning the cell wall) C. The top and D. bottom views of TolC showing the open and 
wide cavity, that’s “closed” at the periplasmic end. 7 
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the OMF CusC, together with the CusAB MFP and transporter pair in E. coli, which has 
been shown to export copper (I) and silver (I).  These heavy metal ions bind and are 
transported to CusB by the fourth system component CusF 29.  Also serving as the exit 
channel for toxins and other proteins, OMFs have been well characterized by protein 
sequence, structure and function.  However, it still remains to characterize the sequence 
of steps involved in the assembly of OMPs with their transporter-MFP counterparts. 
The interactions that allow for the dilation and opening of periplasmic aperture is yet to 
be understood.  Neither have the interactions of the OMP-MFP or OMP-IMP interfaces 
that participate in a functional complex been fully elucidated.  
 
I.1.3 Inner Membrane Proteins (IMPs) 
 Inner membrane transporters (IMPs) are categorized into families of proteins, as 
discussed above. Proteins of the RND superfamily have been identified to expel ions, 
dyes, antimicrobials, etc. A staple RND transporter is E. coli AcrB.  AcrB is a proton 
antiporter used by cells to extrude small molecules out of the cell. Since it was first 
crystallized, there have been over 25 different structures presented 3.  As is common 
with MDE proteins, AcrB structure is one of symmetry.  The N- and C-terminal ends 
contain the three domains of the protein – transmembrane, pore, and OMP docking 
domains (Figure I.0.4A).  The mushroom-shaped AcrB is made up of 12 
transmembrane (TM) α-helices.  Stemming from TM1 and 2, then TM7 and 8, is a 
collection of β-strands and α-helices to make the pore and docking domains located in 
the periplasm2.  Extending past the inner membrane into the cytoplasm and ~70Å into 
the periplasm, the full length of this protein is expected to be ~120Å.  AcrB assembles 
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as a homotrimer, with the monomers linked by a protruding loop from a neighboring 
docking domain (Figure I.0.4B) 2.  Despite this, the protein does not function in a 
symmetric manner.  This transporter protein has two - the distal and proximal - binding 
pockets within each of its three protomers. Each monomer has been shown to have 
different conformations – open, loose, or tight - as they relay a proton across the 
transmembrane domain and simultaneously translocate substrate from the periplasmic 
space outside the cell 38.   
11 
Biochemical and structural studies have shown that AcrB function 
asymmetrically within the cell 3, 39, 40.  The loose, open and tight conformations of the 
AcrB protomers describe the state of the binding pockets, within the pore domain, and 
the relative state of interaction with the substrate.  A loose binding site is open and 
ready to capture substrate.  Once substrate binds, the protein assumes the tight 
conformation and secures the hold on the molecule until expulsion through the inner 
Figure I.0.4 E. coli RND Transporter, AcrB 
A. Topology of the AcrB, mapping the α-helical helices and β-strands of the 
transmembrane, pore, and docking domains. B. Resolved crystal structure of the 
homotrimeric RND transporter (PDB code: 2HRT). C. Close-up analysis of the 
conformational changes within the transmembrane domain, as a proton is relayed across 
the membrane.  Asp 407, Asp 408, and Lys 940 are the key residues within the domain 
as the protein transitions between the loose, tight and open states.  (Adapted and 
modified from 2, 3) 
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pore and out the outer channel. The protein is then in the open transition and relaxes to 
take on the loose form again 3.  Each protomer of the protein undergoes these changes.  
The shape of the binding pockets is related to the conformational changes occurring in 
the transmembrane helices as the drug/proton antiport catalysis occurs.  Asp 407 and 
408 of TM4, and Lys 940 of TM10 have been identified as the key amino acid residues 
involved in the proton relay across the inner membrane (Figure I.0.4C)3.  Despite the 
observations made over the years, the roles of RND transporters in the recruiting of its 
binding partners, especially the corresponding OMP, still remain unclear. This is also 
true of the additional roles within the tripartite complex such as the determination of 
substrate specificity and effects of conformational changes on the complex function. 
 
I.2 Assembly and Mechanism of RND Pumps 
In light of the structural knowledge about each component of the efflux pumps, 
various studies have sought to highlight bipartite interactions, as well as the full 
complex assembly and functionality.  Co-crystallization with its partnering membrane 
fusion protein, the CusAB complex, presents information about the RND-MFP complex 
as would be present in vivo.  The CusA transporter is located in the inner membrane, 
having the same architecture as AcrB 1, 41.  CusA has 12 transmembrane helices and a 
large periplasmic domain – the pore and docking domains – stemming from between 
TM1 and 2, and TM7 and 8.  The CusB adapter protein also models most other 
membrane fusion proteins.  Consisting of the four major domains – the membrane 
proximal, β-barrel, lipoyl, and α-helical hairpin domains – CusB differs in the α-hairpin 
domain, which is made up of three, short helices 41.  In this assembled model, the 
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membrane proximal domain and parts of the β-barrel domain are shown to cap the pore 
and docking domains of CusA.  The third component of the tripartite complex, CusC, 
was recently crystallized and found to resemble the TolC structure 29.  130 Å long, 
CusC is made up of a 12 stranded β-barrel and long α-helical domain and an equatorial 
domain.  Docking the CusC 1 channel protein, two modes of assembly were proposed to 
illustrate the different states during the efflux of heavy metals (Figure I.0.5).  In the first 
model, the end of the CusC α-barrel interacts with the α-helices of CusB.  The second 
model, due to the large hexameric pore of CusB, presents CusC docked on top of CusA 
with the lipoyl domain of CusB at the CusΑ-CusC interface.  The rest of the CusC α-
barrel is wrapped by the CusB α-hairpin domain. 
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All three components of the AcrAB-TolC complex have been resolved 2, 22, 27, 
though there have not been any combinations of the proteins that have been co-
crystallized.  However, there have been many studies that present docked models, as the 
proteins would assemble in vivo 7, 9, 32, 42-45. Based on the structural similarities of the α-
helical domains of OMPs and MFPs, as is found in TolC and AcrA, some believe that 
there is a complete overlap of the proteins at this region 2, 23, 40, 45.  This is the favored 
docking model which supports the hypothesis that the TolC periplasmic end interacts 
directly with the top of the TolC docking domain of AcrB 8.  Another model of the 
tripartite assembly differs from the former in that the coiled coils of TolC and AcrA 
partially overlap 42.  In this model, direct AcrΒ-TolC interactions are broken, having no 
Figure I.0.5 Docking of CusC to CusBA 
A. The α-helices of CusC docks on top of CusB, interacting at the distal ends. Coupled 
with the docked CusBA complex, this forms a conduit from the periplasm and out the 
bacterial cell. B. Based on the size of the CusB hexameric pore, the CusC channel 
protein can be enveloped within it. This allows for direct CusAC interactions at the 
transporter’s docking domain. (Adapted from 1) 
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direct contact.  Instead, they are bridged together by the fusion protein.  There is yet 
another model that suggests a tip-to-tip interaction of the OMP-MFP at the distal loops 
46, 47.  In these models, we see a variability of the docking of the MFP to the transporter 
protein (Figure I.0.6).  Some models present the lipoyl and β-barrel domains of the MFP 
as seated on the docking domain of the RND transporter, while the membrane proximal 
domain interacts with the pore domains.  Other models present the membrane proximal 
domain aligned with the docking domains.  All these models beg the question of the 
flexibility and length between the membranes of the bacterial cell, seeing as each model 
presents different measurements (Figure I.0.6).  Another point of controversy 
concerning assembled efflux pumps pertains to the stoichiometry of each component 
within the complex.  Early research proposed and favored 3 RND:3 MFP:3 OMP ratios 
2. However, in subsequent research using crystallography and chimeric constructs, it has 
Figure I.0.6 Proposed Models of RND Pump Assembly 
The OMF (cyan), transporter protein (green), and membrane fusion proteins (magenta) 
of the AcrAB-TolC tripartite complex, used to depict the different models of protein 
assembly. In the wrapping model, the structurally similar α-helical domains of TolC and 
AcrA are fully aligned. However, in the partial model, only regions below the equatorial 
domain align, one to another.  In this model, the membrane proximal domain is located 
at the docking domain, rather than the pore domain.  The bridging model, as observed in 
the CusABC complex, involves the tip-to-tip interactions of the OMP α-barrel and 




been proven that a 3:6:3 ratio is the more plausible composition of RND efflux pumps 
within the bacterial cell 33, 41, 44. 
Studies of complexes such as the P. aeruginosa MexAΒ-OprM or the E. coli 
AcrAΒ-TolC, MacAΒ-TolC, and the recently resolved CusABC systems have helped 
shed much light on the mechanism of RND efflux pumps (Figure I.0.7).  The co-
crystallization of CusBA introduces a stable, preassembled transporter-MFP complex. 
In vivo, this bipartite complex is assembled and ready to engage the outer membrane 
protein.  Since in vivo proteolysis showed that AcrA undergoes conformational changes 
in the presence of TolC 48, we expect a change in the MFP structure during the 
transition from OMP recruitment to complex stabilization.  Once the complex is 
assembled, the conformational changes within the membrane proximal domain of the 
MFP stimulates the transporter protein. Consequently, as the transporter protein relays 
protons into the cell, the OMP is opened and substrate is ejected out of the cell 7 (Figure 
I.0.7).  All details of this mechanism are not known or confirmed. Assigned the roles of 
Figure I.0.7 Proposed Mechanism of RND Transporters 
In the “Access” state, the preassembled transporter and membrane fusion protein pair 
is resting, ready-to-engage the outer membrane channel protein.  In the “Binding” 
state, MFPs change conformation as they recruit and fully engage the OMP.  The 
complex is now ready to expel substrates.  Stimulation of the transporter protein by 
the MFP, in the “Extrusion” state, causes substrate expulsion coupled with proton 
influx. (Adapted from 7) 
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stabilizing the efflux pump, as well as bridging of the channel and transporter proteins, 
MFPs of these complexes require further investigation. 
In the recently discovered P. aeruginosa RND pump, TriABC-OpmH there are 
two distinct MFPs, TriA and TriB 49.  The constitutively expressed OpmH is a homolog 
of the E. coli TolC.  Together with the RND transporter, TriC, the TriABC-OpmH 
complex is a triclosan and SDS specific pump 33, 49 – triclosan is a substrate of various 
RND efflux pumps, including Escherichia coli AcrAΒ-TolC and P. aeruginosa 
MexAΒ-OprM 33, 50.  We created a covalently linked TriAB construct (TriAxB), where 
the MFPs were expressed as a single polypeptide.  We found that TriAxB assembles as 
a hexameric oligomer, however, this construct form more stable complexes than the 
individually expressed TriAB 33.  More studies with this system, containing the hetero-
hexameric MFP complex, can help further elucidate properties within RND efflux 
pumps. 
 
I.3 Aims and Goals of Dissertation 
 Using this unique RND complex, TriABC-OpmH, as well as the broadly studied 
AcrAΒ-TolC, studies were implemented to resolve some of the unanswered questions 
of the field.  We used biochemical methods such as mutagenesis, crosslinking, surface 
plasmon resonance (SPR), and fluorescence uptake assays.  We sought to find out if the 
TriABC-OpmH complex assembles like other RND systems.  Investigating the amino 
acid interactions at the MFP-OMP, as well as the MFP-IMP interfaces, we characterize 
the roles of the heterodimeric TriAB complex.  We identify the MFP responsible for 
OMP recruitment, as well as the MFP responsible for stimulation of the transporter 
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protein.  We further isolate the MFP responsible for opening the periplasmic aperture of 
the outer membrane channel protein.  Coupling biochemical results with low-resolution 
protein structures, we highlight and propose the sequence events for complex assembly 
and mechanism of substrate expulsion. 
Using the AcrAB-TolC system, we also tested the potential of efflux pump 
proteins as targets of inhibition.  Synthesized inhibitors meant for the RND transporter, 
were used to determine kinetic parameters of said inhibitors and the AcrB transporter 
protein. We established the integrity of these inhibitors, proving their preferred binding 
to AcrB versus binding to AcrA and/or TolC.  
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II. Materials and Experimental Procedures 
II.1 DNA Manipulations 
II.1.1 List of Strains 
Strain Relevant Genotype Source 
JWW3 
Escherichia coli K12 BW25113 ΔompT::Kmr ΔompT-
scar ΔacrAB::Kmr tolC::Tn10 33 
M6394 
GC4468 ΔacrB ΔacrD ΔacrEF::spcr ΔemrB ΔemrY 
ΔentS::camr ΔmacB ΔmdtC ΔmdtF 51 
GKCW101 
M6394 attTn7::mini Tn7T-araC-PBAD-fhuA (FhuA 
ΔC/Δ4LHis) unpublished 
GKCW102 
BW25113 attTn7::mini Tn7T-lacIq-PTAC-fhuA (FhuA 
ΔC/Δ4LHis) unpublished 
GD102 BW25113 ΔtolC-ygiBC 52 
GKCW104 
GD102 attTn7::mini Tn7T-lacIq-PTAC-fhuA (FhuA 
ΔC/Δ4LHis) unpublished 
DH5α 
supE44 DlacU169 hsdR17 recA1 endA1 gyrA96 thi-1 
relA1  
PAO1 Pseudomonas aeruginosa Wild type 53 
PAO1116 
PAO1 ΔmexAB-oprM ΔmexCD-oprJ ΔmexEF-oprN 
ΔmexJK ΔmexXY ΔtriABC 49 
GKCW122 
PAO1 1116 attTn7::mini-Tn7T- Gmr-lacIq-pLAC- 
fhuADCD4L unpublished 
JWW9 





PAO1116 attTn7:: mini-Tn7T-Tpr-araC-PBAD-opmH 
(OpmHE173C, His) This Study 
JWW11 JWW10 ΔopmH::Gmr This Study 
JWW12 
PAO1116 attTn7:: mini-Tn7T-Tpr-araC-PBAD-opmH 
(OpmHK182C, His) This Study 
JWW13 JWW12 ΔopmH::Gmr This Study 
JWW14 
PAO1116 attTn7:: mini-Tn7T-Tpr-araC-PBAD-opmH 
(OpmHI392C, His) This Study 
JWW15 JWW14 ΔopmH::Gmr This Study 
JWW16 
PAO1116 attTn7:: mini-Tn7T-Tpr-araC-PBAD-opmH 
(OpmHV396C, His) This Study 
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W4680AE Escherichia coli K-12 ∆acrAB::kan ∆acrEF::spe 54 
ZK796 Escherichia coli MC4100 ∆tolC:: tet 55 
AG100AX Escherichia coli AG100 ∆acrAB::kan ∆acrEF::spe 54 
 
II.1.2 List of Plasmids 
Plasmids Relevant Genotype Source 
pBSPII (KS-/SK-) Cbr; broad-host-range cloning vector 56 
pPS1824 Cbr; pBSPII Plac-triABC; Bla
r 49 
pBSP-AxBC 
Cbr; pPS1824 expressing triAxBC;TriA 
and TriB are expressed as a fusion protein 33 
pBSP-AR130DxBC 
Cbr; expresses triAxBC; mutant triA 
(TriAR130D) This Study 
pBSP-AG350CxBC 
Cbr; expresses triAxBC; mutant triA 
(TriAG350C) This Study 
pBSP-AxBR118DC 
Cbr; expresses triAxBC; mutant triB 
(TriBR118D) This Study 
pBSP-AxBG339CC 
Cbr; expresses triAxBC; mutant triB 
(TriBG339C) This Study 
pBAD33 
Cmr; expression vector; arabinose 
inducible promoter 57 
pBAD33-ABC 
Cmr; expresses triABC; expresses Strep-
tagged TriC 33 
pBAD33-AR130DBC 
















Cmr; expresses triAxBC; TriA and TriB 
are expressed as a fusion protein; 
expresses Strep-tagged TriC 33 
pBAD33-AxBR133CC 
Cmr; expresses triAxBC; mutant triB 
(TriBR133C) This Study 
pBAD-A Apr; expresses triA; 6-His tagged TriA 33 
pBAD-B Apr; expresses triB; 6-His tagged TriB 33 
pBAD-C(His) Apr; expresses triC; 6-His tagged TriC 33 
pUC151B Apr; expresses acrAB; 6-His tagged AcrB 32 
   





pTJ1-opmH Apr; Tpr; expresses opmH (OpmHHis) 
33
 
pTJ1-opmH-E176C Apr; Tpr; expresses opmH (OpmHE173C, His) This Study 
pTJ1-opmH-K182C Apr; Tpr; expresses opmH (OpmHK182C, His) This Study 
pTJ1-opmH-I392C Apr; Tpr; expresses opmH (OpmHI392C, His) This Study 
pTJ1-opmH-V396C Apr; Tpr; expresses opmH (OpmHV396C, His) This Study 
pTNS2 
Apr; Helper plasmid expressing Tn7 
transposase proteins TnsABCD 60 
pBSP-AA116CxBC 
Cbr; expresses triAxBC; mutant triA 
(TriAA116C) This Study 
pBSP-AA134CxBC 
Cbr; expresses triAxBC; mutant triA 
(TriAA134C) This Study 
pBSP-AK138CxBC 
Cbr; expresses triAxBC; mutant triA 
(TriAK138C) This Study 
pBSP-AG139CxBC 
Cbr; expresses triAxBC; mutant triA 
(TriAG139C) This Study 
pBSP-AE145CxBC 
Cbr; expresses triAxBC; mutant triA 
(TriAE145C) This Study 
pBSP-AxBA104CC 
Cbr; expresses triAxBC; mutant triB 
(TriBA104C) This Study 
pBSP-AxBE122CC 
Cbr; expresses triAxBC; mutant triB 
(TriBE122C) This Study 
pBSP-AxBR126CC 
Cbr; expresses triAxBC; mutant triB 
(TriBR126C) This Study 
pBSP-AxBS127CC 
Cbr; expresses triAxBC; mutant triB 
(TriBS127C) This Study 
pBSP-AxBR133CC 
Cbr; expresses triAxBC; mutant triB 
(TriBR133C) This Study 
pBAD33-AxBC 
Cmr; expresses triAxBC; TriA and TriB 
are expressed as a fusion protein; 
expresses Strep-tagged TriC 33 
pBAD33-AxBR133CC 
Cmr; expresses triAxBC; mutant triB 
(TriBR133C) This Study 
pBAD-C(His) Apr; expresses triC; 6-His tagged TriC 33 
   
pAcrA (His) Apr; expresses acrA; 6-His tagged AcrA 20 
pAcrAD149C 
Apr; expresses acrA; 6-His tagged AcrA; 
mutant acrA (AcrAD149C) This Study 
pAcrAG363C 
Apr; expresses acrA; 6-His tagged AcrA; 
mutant acrA (AcrAG363C) 
48
 
pTolC (His) Apr; expresses tolC; 6-His tagged TolC 32 
pTolCYFRE 
Apr; expresses tolC; 6-His tagged TolC; 




Apr; expresses tolC; 6-His tagged TolC; 
mutant tolC (TolCQ142C) 
63 
pTolCA269C 
Apr; expresses tolC; 6-His tagged TolC; 
mutant tolC (TolCA269C) 
63 
pTolCD374C 
Apr; expresses tolC; 6-His tagged TolC; 
mutant tolC (TolCD374C) 
63 
pTolCK383C 
Apr; expresses tolC; 6-His tagged TolC; 
mutant tolC (TolCK383C) This Study 
pYFREQ142C 
Apr; expresses tolCYFRE; 6-His tagged 
TolC; mutant tolCYFRE (YFREQ142C) 
63 
pYFREA269C 
Apr; expresses tolCYFRE; 6-His tagged 
TolC; mutant tolCYFRE (YFREA269C) 
63 
pYFRED374C 
Apr; expresses tolCYFRE; 6-His tagged 
TolC; mutant tolCYFRE (YFRED374C) 
63 
pYFREK383C 
Apr; expresses tolCYFRE; 6-His tagged 
TolC; mutant tolCYFRE (YFREK383C) This Study 
   
pAcrAG362C 
Apr; expresses acrA; 6-His tagged AcrA; 
mutant acrA (AcrAG362C) 
48 64 
pAcrBS1043C 
Apr; expresses acrB; 6-His tagged AcrB; 




Apr; expresses acrBS1043C; 6-His tagged 
AcrB; mutant acrB (AcrBD408A, S1043C) This Study 
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II.1.4 Site-Directed Mutagenesis 
 All point mutations were introduced using either the Stratagene QuickChange-
XL or Lightning site-directed mutagenesis kit, as recommended by the manufacturer. 
Briefly, the resulting PCR products were treated with DpnI, transformed into DH5α 
competent cells and plated on Luria Bertani (LB) agar containing ampicillin (100 
µg/ml). For each mutant, at least two plasmids were purified and sequenced to assess 
the presence of the desired mutation.  All mutations were verified by DNA sequencing 
at the Oklahoma Medical Research Foundation (OMRF) DNA Sequencing Facilities. 
 
II.1.5 OpmH Cloning  
All strains and plasmids constructed in this study are shown in tables above.  
Mutations were introduced into pTJ1-opmH using manufacturer’s instructions 
(QuikChange Lightning, Agilent Technologies). Mutated mini Tn7 cassettes were 
integrated onto the chromosome of PAO1116 via co-electroporation with pTNS2 and 
selected on LB plates containing trimethoprim (15 µl/ml). Confirmed integrants were 
then subjected to mating with E. coli Sm10/pPS1283, upon mating haploid deletion 
strains were selected on LB media supplemented with 30 µg/ml gentamicin, 5% sucrose 
and 1% arabinose. PCR and sequencing (OMRF) were performed to confirm the native 
opmH gene had been deleted and that the cysteine mutant opmH gene was present under 
the control of the arabinose promoter. 
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II.2 Minimal Inhibitory Concentration (MIC) Determinations 
Overnight cultures of P. aeruginosa or E. coli carrying indicated constructs were 
diluted 1 to 100 in LB broth supplemented with a selection marker grown at 37°C with 
shaking for 5 hours.  MICs of antimicrobial agents were measured using the two-fold 
dilution technique in 96-well microtitre plates 65. At an optical density at 600 nm 
(OD600) of ~1.0, cells were inoculated at a density of 5x10
4 cells per ml in LB in the 
presence of two-fold increasing concentrations of substrates under investigation.  The 
cultures were incubated for 18-24 hours, and the lowest concentration that completely 
inhibited bacterial growth was designated the MIC. When required, protein expression 
was induced by adding 1.0 mM IPTG, 0.2% L-arabinose, or 1% L-arabinose to cell 
cultures at OD600 of ~0.3-0.5, and cells were further incubated at 37°C for 3 more hours 
till OD600 ~1.0-1.2.  
 
II.3 Protein Purification 
II.3.1 AcrA 
For the purification of AcrA and its cysteine variants, W4680AE cells carrying 
the appropriate plasmid from fresh transformation were inoculated into 15 ml LB 
containing 100 µg/ml ampicillin.  After 2 hours, 10 ml of cells were reinoculated into 1 
L LB medium. The production of proteins was induced by the addition of isopropyl-1-
thio-β-galactoside (IPTG), 0.1 mM final concentration, after 3 hours of growth then left 
to grow overnight.  Cells were harvested by low speed centrifugation at 3,220 x g for 20 
mins at 4°C then washed with 10 mM Tris-HCl (pH 8.0) and centrifuged. The pellets 
were resuspended in 10 mM Tris-HCl (pH 8.0), 5 mM ethylenediaminetetraacetate 
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(EDTA), 1 mM phenylmethylsulfonyl fluoride (PMSF) and 100 µg/ml lysozyme and 
incubated on ice for 30 mins. The cells were lysed thrice for 30-45 sec using an 
ultrasonicator (Branson). Unbroken cells were removed by low speed centrifugation at 
3,220 x g for 30 mins. Cell membranes were isolated by high speed centrifugation at 
>100,000 x g for 1 hr at 4°C in Beckman Ti-45, then washed for an hour at >100,000 x 
g after resuspension in 20 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM PMSF. 
The membrane pellets were resuspended in 20 mM Tris-HCl (pH 8.0), 500 mM NaCl, 1 
mM PMSF, and 5 mM Imidazole then sonicated before adding n-dodecyl β-D-maltoside 
(DDM) to a final concentration of 2%.  Membranes were solubilized overnight and 
centrifuged at >100,000 x g for 30 mins at 4°C then loaded onto a NTA column charged 
with 50 mM CuSO4. Samples were washed in 20 mM Tris-HCl (pH 8.0), 500 mM 
NaCl, 1 mM PMSF, and 0.03% DDM buffer with a gradient of imidazole 
concentrations. For binding buffers with 5 mM, 25 mM, and 50 mM Imidazole, one 
fraction of 10-20 column volumes (CVs) was collected. Five fractions of 2 CVs were 
collected for binding buffer with 100 mM Imidazole. AcrA was eluted in 20 mM Tris-
HCl (pH 8.0), 500 mM NaCl, 1 mM PMSF, 0.03% DDM, and 500 mM Imidazole – 
three fractions of 2 CVs.  Purified proteins were dialyzed (one round with 10 mM 
EDTA) and stored in 20 mM Tris-HCl (pH 8.0), 500 mM NaCl, 1 mM PMSF, and 
0.03% DDM until used in experiments.  All collected fractions are separated by 10% 




For the purification of AcrB and its cysteine variants, overnight cultures of 
AG100X cells carrying the appropriate plasmid was reinoculated (1:100) in 1 L LB 
containing 100 µg/ml ampicillin.  The production of proteins was induced by the 
addition of isopropyl-1-thio-β-galactoside (IPTG), 1.0 mM final, after 4 hours of growth 
then left to grow an additional 3 hours.  Cells were harvested by low speed 
centrifugation at 5,000 rpm for 20 mins at 4°C then the pellets were resuspended in 10 
mM Tris-HCl (pH 8.0), 5 mM ethylenediaminetetraacetate (EDTA), 1 mM 
phenylmethylsulfonyl fluoride (PMSF) and 100 µg/ml lysozyme and incubated on ice 
for 30 mins. The cells were lysed thrice for 30-45 sec using an ultrasonicator (Branson). 
Unbroken cells were removed by low speed centrifugation at 3,220 x g for 30 mins. 
Cell membranes were isolated by high speed centrifugation at >100,000 x g for 1 hr at 
4° in Beckman Ti-45, then washed twice for 1.5 hours at >100,000 x g in 20 mM Tris-
HCl (pH 8.0), 500 mM NaCl, and 1 mM PMSF with and without 0.2% Triton X100, 
respectively. The membrane pellets were resuspended in 20 mM Tris-HCl (pH 8.0), 500 
mM NaCl, 1 mM PMSF, 5 mM Imidazole and 2% n-dodecyl β-D-maltoside (DDM).  
Membranes were solubilized for 4 hours or overnight and centrifuged at >100,000 x g 
for 30 mins at 4°C then loaded onto a NTA column charged with 50 mM CuSO4. 
Samples were washed in 20 mM Tris-HCl (pH 8.0), 500 mM NaCl, 1 mM PMSF, and 
0.03% DDM buffer with a gradient of imidazole concentrations. For binding buffers 
with 5 mM, 20 mM, and 50 mM Imidazole, one fraction of 10-20 column volumes 
(CVs) was collected. Two fractions of 2.5 CVs were collected for binding buffer with 
100 mM Imidazole. AcrB was eluted in 20 mM Tris-HCl (pH 8.0), 500 mM NaCl, 1 
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mM PMSF, 0.03% DDM, and 500 mM Imidazole – five fractions of 1 CV.  Purified 
proteins were dialyzed (one round with 10 mM EDTA) and stored in 20 mM Tris-HCl 
(pH 8.0), 500 mM NaCl, 1 mM PMSF, and 0.03% DDM until used in experiments. All 
collected fractions are separated by 10 % SDS-PAGE gel electrophoresis and visualized 
by Coomassie Blue Staining. 
 
II.3.3 TolC 
In order to purify TolC and its cysteine variants, overnight cultures of ZK796 
cells carrying the appropriate plasmid was reinoculated (1:100) into20 mL LB 
containing 100 µg/ml ampicillin.  After ~1 hour, 10 ml of cells was reinoculated into 1 
L LB medium.  The production of proteins was induced by the addition of IPTG, 0.2 
mM final, when OD600 is ~0.3-0.5, then left to grow overnight.  Cells were harvested by 
low speed centrifugation at 5,000 rpm for 20 mins at 4°C then the pellets were 
resuspended in 20 mM Tris-HCl (pH 7.5), 5 mM MgCl2, 1 mM phenylmethylsulfonyl 
fluoride (PMSF) and 0.05 mg/ml DNAse and incubated on ice for 30 mins. The cells 
were lysed by French press, thrice at 1000 psi. Unbroken cells were removed by low 
speed centrifugation at 3,220 x g for 30 mins. Cell membranes were isolated by high 
speed centrifugation at >100,000 x g for 1 hr at 4°C in Beckman Ti-45, then washed 
twice for 1.5 hours at >100,000 x g in 20 mM Tris-HCl (pH 7.5), 100 mM NaCl, 20 
mM MgCl2 and 1 mM PMSF with and without 0.5% Triton X100, respectively. The 
membrane pellets were resuspended in 20 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM 
PMSF, 5 mM Imidazole and 1% n-dodecyl β-D-maltoside (DDM).  Membranes were 
solubilized for 5 hours or overnight and centrifuged at >100,000 x g for 30 mins at 4°C 
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then loaded onto a NTA column charged with 50 mM CuSO4. Samples were washed in 
20 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM PMSF, and 0.03% DDM buffer with a 
gradient of imidazole concentrations. For binding buffers with 5 mM, 20 mM, 50 mM 
and 10 mM Imidazole, one fraction of 10-20 column volumes (CVs) was collected.  
TolC was eluted in 20 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM PMSF, 0.03% 
DDM, and 500 mM Imidazole – four fractions of 1 CV.  Purified proteins were dialyzed 
(one round with 10 mM EDTA) and stored in 20 mM Tris-HCl (pH 7.5), 500 mM 
NaCl, 1 mM PMSF, and 0.03% DDM until used in experiments. All collected fractions 
are separated by 10 % SDS-PAGE gel electrophoresis and visualized by Coomassie 
Blue Staining. 
 
II.3.4 TriA, TriB, TriC, TriABC, and TriAxBC and Variants 
In order to purify Tri proteins and cysteine variants, overnight cultures of JWW3 
cells carrying the appropriate plasmid were reinoculated (1:100) into 1 L LB containing 
the appropriate resistance marker – 100 µg/ml ampicillin and/or 12.5 µg/ml 
chloramphenicol.  When necessary, production of proteins was induced by the addition 
of 0.2% L-arabinose, when OD600 is ~0.3-0.5 then left to grow for 5 hours.  Cells were 
harvested by low speed centrifugation at 5,000 rpm for 20 mins at 4°C then the pellets 
were resuspended in 20 mM Tris-HCl (pH 7.5), 5 mM MgCl2, 1 mM 
phenylmethylsulfonyl fluoride (PMSF) and 0.05 mg/ml DNAse and incubated on ice for 
30 mins. The cells were lysed thrice for 30-45 sec using an ultrasonicator (Branson). 
Unbroken cells were removed by low speed centrifugation at 3,220 x g for 30 mins. 
Cell membranes were isolated by high speed centrifugation at >100,000 x g for 1 hr at 
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4°C in Beckman Ti-45, then washed for 1.5 hours at >100,000 x g in 10 mM Tris-HCl 
(pH 7.5), 100 mM NaCl, and 1 mM PMSF.  The membrane pellets were resuspended in 
50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM PMSF, 10 mM Imidazole and 2% n-
dodecyl β-D-maltoside (DDM).  Membranes were solubilized overnight and centrifuged 
at >100,000 x g for 30 mins at 4°C then loaded onto a NTA column charged with 50 
mM CuSO4. Samples were washed in 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM 
PMSF, and 0.03% DDM buffer with a gradient of imidazole concentrations. For 
binding buffers with 5 mM, 20 mM, and 40 mM Imidazole, one fraction of 10-20 
column volumes (CVs) was collected.  Tri proteins were eluted in 50 mM Tris-HCl (pH 
7.5), 150 mM NaCl, 1 mM PMSF, 0.03% DDM, and 400 mM Imidazole – seven 
fractions of 0.5 CV.  Purified proteins were dialyzed (one round with 10 mM EDTA) in 
50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM PMSF, and 0.03% DDM when ready 
to be used in experiments. All collected fractions are separated by 12 % SDS-PAGE gel 
electrophoresis and visualized by Coomassie Blue Staining. 
 
II.3.5 OpmH 
In order to purify Tri proteins and cysteine variants, overnight cultures of JWW3 
cells carrying the appropriate plasmid was reinoculated (1:100) into 1 L LB containing 
the appropriate resistance marker – 100 µg/ml ampicillin and/or 12.5 µg/ml 
chloramphenicol.  When necessary, production of proteins was induced by the addition 
of 0.2% L-arabinose, when OD600 is ~0.3-0.5 then left to grow for 5 hours.  Cells were 
harvested by low speed centrifugation at 5,000 rpm for 20 mins at 4°C then the pellets 
were resuspended in 20 mM Tris-HCl (pH 7.5), 5 mM MgCl2, 1 mM 
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phenylmethylsulfonyl fluoride (PMSF) and 0.05 mg/ml DNAse and incubated on ice for 
30 mins. The cells were lysed thrice for 30-45 sec using an ultrasonicator (Branson). 
Unbroken cells were removed by low speed centrifugation at 3,220 x g for 30 mins. 
Cell membranes were isolated by high speed centrifugation at >100,000 x g for 1 hr at 
4°C in Beckman Ti-45, then washed for 1.5 hours at >100,000 x g in 10 mM Tris-HCl 
(pH 7.5), 100 mM NaCl, and 1 mM PMSF.  The membrane pellets were resuspended in 
50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM PMSF, 10 mM Imidazole and 2% n-
dodecyl β-D-maltoside (DDM).  Membranes were solubilized overnight and centrifuged 
at >100,000 x g for 30 mins at 4°C then loaded onto a NTA column charged with 50 
mM CuSO4. Samples were washed in 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM 
PMSF, and 0.03% DDM buffer with a gradient of imidazole concentrations. For 
binding buffers with 5 mM, 20 mM, 40 mM and 75 mM Imidazole, one fraction of 10-
20 column volumes (CVs) was collected.  OpmH protein was eluted in 50 mM Tris-HCl 
(pH 7.5), 150 mM NaCl, 1 mM PMSF, 0.03% DDM, and 400 mM Imidazole – five 
fractions of 1 CV.  Purified proteins were dialyzed (one round with 10 mM EDTA) in 
50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM PMSF, and 0.03% DDM when used in 
experiments. All collected fractions are separated by 10 % SDS-PAGE gel 
electrophoresis and visualized by Coomassie Blue Staining. 
 
II.4 Fluorophore Uptake Assays 
E. coli GKCW101 cells carrying indicated constructs were inoculated into 5 ml 
LB medium with 100 µl/ml and grown at 37oC with shaking at 200 rpm to OD600~0.3. 
At this optical density, cells were induced with 0.1% L-arabinose grown until the cells 
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reached OD600~1.0. Cells were then pelleted at room temperature by centrifugation for 
15 min. The pellet was resuspended and washed in 25 ml of the 50 mM KPO4
3-, 1 mM 
MgCl2, and 0.4% glucose (PMG) buffer. Pellet was resuspended to an OD600~1.0 in 
PMG buffer and kept at room temperature during the course of the experiment.  Uptake 
assays were performed in a Tecan Spark 10M micro-plate reader in a fluorescence 
mode.  At 20, 000 Z-position and 100 gain, fluorescence intensities were measured for 
10 minutes. 
 
II.5 Spontaneous Sulfide Crosslinking 
 Overnight JWW9, JWW11, JWW13, and JWW15 cultures were reinoculated in 
5 ml LB broth, supplemented with selection marker and 1% L-arabinose, at 1:100 
dilutions and grown at 37°C. Cells were harvested after reaching OD600 ~1.0 (after 
about 6 hours) and washed in 1X phosphate buffer saline (PBS).  Cell pellets were 
resuspended in 1 ml PBS with 2 mM n-ethyl-maleimide (NEM) and incubated for 5 
minutes at room temperature; afterwards, cells were washed in PBS buffer. (At this 
stage, cells can be frozen for storage and later use.)  Cell pellets were resuspended in 10 
mM Tris-HCl (pH 8.0), 5 mM ethylenediaminetetraacetate (EDTA), and 100 µg/ml 
lysozyme and incubated on ice for 30 mins. The cells were lysed thrice for 30-45 sec 
using an ultrasonicator (Branson). Unbroken cells were removed by low speed 
centrifugation at 3,220 x g for 30 mins. Cell membranes were isolated by high speed 
centrifugation at >100,000 x g for 1 hr at 4° in Beckman TLA 55. Membranes were 
washed and resuspended in 50 µl 10 mM Tris-HCl (pH 8.0). Membrane proteins were 
quantified by the BSA Bradford Assay, and equal amounts were separated by SDS-
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PAGE gel electrophoresis. Samples were transferred onto polyvinylidene fluoride 
(PVDF) membranes, and proteins are identified by immunoblotting.  5 µg total 
membranes were probed by anti-TriB serum 33, while 10 µg of proteins was used for 
detection by the anti-His antibody (Pierce). 
 
II.6 Azithromycin Spot Assay 
 Overnight cultures of P. aeruginosa carrying the indicated constructs were 
diluted 1:100 in LB broth supplemented with 1% L-arabinose and 200 µg/ml and grown 
at 37°C with shaking at 200 rpm for 5 hours. Four ml of molten soft agar (50% LB, 
50% LBA, supplemented with 1% arabinose), was inoculated with 300 µl of freshly 
grown culture and poured over LBA plates supplemented with 1% arabinose. Soft agar 
was allowed to solidify and spotted with four 10 µl spots of 0.15 µg/ml azithromycin in 
DMSO (1.5 µg per spot). Spots were allowed to absorb into agar for 15 minutes prior to 
incubation at 37°C for 18 hours. Zones of inhibition were recorded and are an average 
of 8 spots per strain were determined and shown. Standard error and Student’s T-test 
with two-tailed unpaired parameters were calculated on samples using Excel. P values 
of 0.05 were considered statistically significant. 
 
II.7 Protein Labeling with NANOGOLD® 
 Purified proteins were dialyzed into 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 
mM PMSF, and 0.03% DDM, no imidazole.  Thiol groups were reduced in the equal 
volume of tris(2-carboxyethyl)phosphine (TCEP) resin – the duration of reduction was 
based on recommended times given by the Thermo Pierce manual.  Reduced protein 
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was eluted off the TCEP resin in 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM 
PMSF, and 0.03% DDM – five fractions of one column volume was collected in 
separate tubes.  Proteins concentrations were estimated for each fraction by incubating 
in BioRad Protein Assay dye and measuring Abs at 595 nm. Peak fractions were 
combined then incubated with fresh monomaleimido NANOGOLD® (Nanoprobes) in 2 
molar excess. Excess NANOGOLD® was removed from the sample using Nap™-5 
Sephadex™ G-25 DNA Grade columns (GE Healthcare) and proteins were dialyzed 
into 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 0.03% DDM. 
 
II.8 Negative Staining Electron Microscopy (EM) 
II.8.1 Sample Preparation and Image Acquisition.  
EM studies were carried by Lucien Fabre and Isabelle Rouiller at McGill 
University, Canada.  Purified TriC and TriAxBC samples (each 5 µL diluted to ~50 
µg/ml) were applied onto negatively glow-discharged carbon-coated grids (400 mesh, 
copper grid) for 1 min. Excess liquid was removed by blotting with filter paper. Freshly 
prepared 1.5% uranyl formate (pH 5.0) was added (5 µl) for 1 min and then blotted dry. 
Digital micrographs were collected using a FEI Tecnai G2 F20 microscope operated at 
200 kV and equipped with a Gatan Ultrascan 4k x 4k Digital CCD Camera. The images 
were recorded at defocus between 1.0−2.0 μm at a magnification of 134,010X at the 
camera and a pixel size of 1.12 Å. 
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II.8.2 EM Data Processing and Image Analysis.  
Contrast transfer function parameters were determined using ctffind3 66. Protein 
particles were boxed using an in-house autoboxing software using an input template 
obtained by averaging ~100 particles randomly oriented. After extraction, particles were 
binned 2X for a final box size of 128x128 pixels and a resulting pixel size of 2.24 Å at 
specimen level. 84,288 particles were collected for EM reconstruction of TriC. These 
particles were initially submitted to Iterative Stable Alignment and Clustering (ISAC) 
2D classification 67.  Further analysis was performed using 21,522 validated by this 
procedure. An initial reference map generated de novo using PRIME 68 and was used 
for ML3D classification and 3D refinement using Relion 1.3 69. 3D classification of the 
validated particles was initiated with 7 seeds and a tau of 4. Two of the classes obtained 
contained few particles and the corresponding particles were discarded. The handiness 
of the maps was visually determined one in respect of another and by comparison with 
the high resolution model. 16,336 and 11,393 particles were analyzed for TriAxBC and 
TriAxBR133CC-•NANOGOLD® in a similar fashion. ML3D classification was 
performed using 4 seeds and a tau value of 4. The initial model was the TriC de novo 
volume filtered at 60 Å. This classification led to 4 identical classes for both data set. 
An additional refinement was performed including all the particles. All structures have 
a resolution estimated between 20 to 25 Å. 
 
II.9 Proteolysis 
For in vivo proteolysis, cells were grown to OD600 ~1.0 then harvested and 
washed twice in 20 mM Tris-HCl (pH 7.5) and 100 mM NaCl.  Cell pellets were 
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resuspended in 200 µl 20 mM Tris-HCl (pH 7.5), 5 mM EDTA, and 20% sucrose then 
aliquoted and treated with increasing concentrations of trypsin.  Samples were 
incubated for 1 hour in 37°C water bath. The reaction was stopped with sample buffer 
with 2-mercaptoethanol (βME), boiled for 5 minutes, and separated by SDS-PAGE gel 
electrophoresis.  Proteins fragments were visualized by immunoblotting using anti-TriA 
and anti-TriB serums 33.  Purified proteins were treated the same as whole cells for 
proteolysis.  Fragments visualized by silver staining or by immunoblotting with 
corresponding polyclonal rabbit antibodies. 
 
II.10 Pyrene Maleimide Labeling 
 Purified AcrA was dialyzed into 20 mM Tris-HCl (pH 8.0), 500 mM NaCl and 
0.03% DDM (AcrA Buffer A) while purified TolC proteins were dialyzed into 20 mM 
Tris-HCl (pH 8.0), 100 mM NaCl and 0.03% DDM (TolC Buffer A).  Thiol groups 
were reduced in the equal volume of tris(2-carboxyethyl)phosphine (TCEP) resin – the 
duration of reduction was based on recommended times given by the Thermo Pierce 
manual.  Five fractions of protein, one column volume, were collected in the respective 
Buffer A.  Protein concentrations were estimated for each fraction by incubating in 
BioRad Protein Assay dye and measuring Abs at 595 nm. Peak fractions were combined 
then incubated with fresh pyrene maleimide in 20 molar excess. Excess pyrene was 
removed from the sample using Nap™-5 Sephadex™ G-25 DNA Grade columns (GE 
Healthcare) and dialyzed into 20 mM MES (pH 6.0), 0.03% DDM and 150 mM NaCl 
buffer for experiments. 
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II.11 Fluorescence Spectroscopy 
Pyrene labeled proteins (0.5 – 1.0 ml) were used for fluorescence spectroscopy 
using the Shimadzu RF-5301 spectrofluorometer.  After mixing labeled samples, pyrene 
was excited with light at 337 nm and the emission spectrum readout was used for 
analysis. If the two pyrene rings were within 10 Å of each other, a red shift emission 
peak at ~470 nm would be observed for the excimers. However, if the labeled positions 
were not within range for stacking, the singular molecules were observed at 
wavelengths of 375-395 nm 70.  At bandwidths of 3 nm, automatic response time, and 
super (1nm interval) scan speeds, pyrene molecules were excited at 337 nm and the 
emission light intensities were measured between 360 and 560 nm.  Scan speed was 
reduced to slow in later experiments, when protocol was being optimized.  For 
Quantitative experiments using free pyrene, the probe was excited at 337 nm and the 
emission intensities of the first of the twin peaks was measured at 376 nm – 
concentrations were set to mg/ml, bandwidths 5 nm, and response time was automatic.  
Time course experiments measured the emission of pyrene at 465 nm through 3 nm 
bandwidths.  Readings were recorded every 2 seconds for 301 readings (10 minutes). 
 
II.12 Surface Plasmon Resonance 
II.12.1 Thiol Coupling 
Purified AcrA and AcrB were dialyzed into 20 mM Tris-HCl (pH 8.0), 500 mM 
NaCl, 1 mM PMSF, and 0.03% DDM while purified TolC proteins were dialyzed into 
20 mM Tris-HCl (pH 8.0), 100 mM NaCl and 0.03% DDM.  Thiol groups were 
reduced, in equal volumes of protein and tris(2-carboxyethyl)phosphine (TCEP) resin, 
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immediately before the experiments.  Collected fractions were checked for protein 
content and concentrations, the highest were used for immobilization. 
 
II.12.2 Immobilization 
 For the SensíQ® Pioneer and Biacore 3000, new sensor chip surfaces (COOH5 
and CM5, respectively) are cleaned with 20 mM CHAPS in 20 mM MES 6.0, 150 mM 
NaCl, and 0.03% DDM running buffer (RB) after the system had been primed twice 
with RB. Equal volumes of 0.4 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) 
and 0.1 N-hydroxysuccinimide (NHS) are injected over the chip surface for 2 mins at 5-
10 µl/min. The activated surface was immediately reacted with 2-(2-
pyridinyldithio)ethaneamine (PDEA), 80 mM in 0.1 M NaBO3 pH 8.5), to introduce a 
disulfide bond, for 4 mins at 5-10 µl/min.  This disulfide is the position at which 
proteins of interest compete and bind to.  Cysteine-containing proteins were diluted in 
10 mM MES (pH 5.0) and 0.03% n-dodecyl β-D-maltoside (DDM) and injected on the 
surface in varying times and replicates at 5-10 µl/min. For the control surface, 10 mM 
MES (pH 5.0) and 0.03% DDM was injected to mock the protein surfaces.  Unreacted 
chemistry was capped with cysteine in MES (pH 5.0) and 1 mM NaCl, and surfaces 
were washed with 40 mM CHAPS in Tris-HCl (pH8.0) to remove non-specific binding.  
Immobilized protein was calculated by subtraction the surface density post PDEA from 
the densities prior to cysteine capping. 
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II.12.3 Data Collection and Normalization 
 For protein-protein interactions and protein-inhibitor experiments, flow rates 
were set to 40-50 µl/min.  In the case of inhibitor experiments, the running buffer was 
supplemented with 5% DMSO to match the conditions of solubilization.  Samples were 
injected onto immobilized and control surfaces for 1 to 2 minutes at 40-50 µl/min.  
Quick injects of 40 mM CHAPS (pH 8.0) was use to clean surface as necessary – 
between concentration dependent injections and/or between different samples.  Binding 
curves were normalized by aligning and subtracting control surface responses, as well 
as the sensogram of RB (with DMSO) corresponding to the EPI concentration.  Fitting 
and kinetic parameters were determined from normalized sensograms, using Qdat© on 
the SensíQ® Pioneer, and BIAEvaluation 2.1© for the Biacore 3000 unit or Excel. 
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Chapter 1. Non-Equivalent Roles of TriA and TriB in Efflux 
TriABC-OpmH of P. aeruginosa is a unique RND system with two 
independently expressed MFPs – TriA and TriB.  Using this complex as the model of 
studying RND transporters, we sought to understand the role of TriA and TriB proteins 
within the assembled complex.  We established that TriA and TriB can be covalently 
linked to express and assemble heterodimers within a functional complex 33.  We 
introduced point mutations in the coiled coil and membrane proximal (MP) domains of 
TriAB, based on amino acid residues in AcrA (Arg 128 and Gly 363)48, 71, which caused 
a loss of complex function but did not affect complex assembly.  We established that 
each MFP has independent roles within the complex. Using analogous aspartic acid 
(TriAR130D and TriBR118D) mutants of the α-helical domain (Figure 1.0.1), we found that 
TriA is responsible for the recruitment and stabilization of the efflux pump by means of 
interactions with the OMF.  Cysteine mutations in a conversed glycine position 
(TriAG350C and TriBG339C) of the MP domain proved that TriB plays an important role in 
Figure 1.0.1 Protein Structures of TriA and TriB 
Crystal structure of TriA and TriB based on MexA (PDB code: 2V4D) with 
highlighted amino acids used in mutagenesis.  Mutations of the coiled coil (magenta) 
and membrane proximal domains (green) were used in uptake and proteolysis studies.  
TriB Arg 133 (blue) was labeled with NANOGOLD® and used for negative staining 
electron microscopy (EM) 
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interacting with the transporter, TriC, for a functional complex.  In this study, we 
reconstituted the efflux activity of TriABC in E. coli cells and characterized the 
functional properties of TriA and TriB. We also find that TriABC takes on different 
conformations in the presence and absence of the outer membrane channel. 
 
1.1 TriABC and TriAxBC are Expressed and Functional in E. coli GKCW101 
(∆9FhuA) 
In order to test the functionality of TriABC complex we expressed these proteins 
in E. coli GKCW101 (∆9FhuA∆C/∆4L or ∆9FhuA) – a strain which lacks nine 
transporters that function with TolC, and has the outer membrane permeabilized 
(expressed FhuA proteins lacked their cork domain and 4 extracellular loops) 
(Krishnamoorthy et. al submitted).  The permeability barrier of the Gram-negative 
bacterial cell wall limits the uptake of compounds into the cell, as well as masks the 
activity of efflux pumps.  We used E. coli GKCW101 in order to reduce limiting factors 
at the outer membrane.  We expressed the TriABC complex and its covalently linked 
variant, TriAxBC, in ∆9FhuA (Figure 1.0.2) and found that the cell’s susceptibility to 
Figure 1.0.2 Expression Analysis of TriABC and TriAxBC 
100 µg membrane fractions of GKCW101 cells, producing FhuA under the arabinose 
promoter, were analyzed by SDS-PAGE.  Separated proteins were transferred onto 
PVDF membranes and analyzed by anti-TriA and anti-TriB immunoblotting. 
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SDS and triclosan decreased in the presence of this complex (Table 1.0.1). The 
measured minimal inhibitory concentrations (MICs) were comparable to that of the 
native, and polyspecific AcrAB. 
We found that induction of the FhuA pore production by 0.1% L-arabinose 
affected the susceptibility to SDS, but not triclosan.  The MICs of SDS in cells carrying 
TriABC encoding plasmids in the absence of FhuA was greater than 2.5 mg/ml, 
compared to 312 µg/ml when the pore was expressed from the chromosome. These 
values were 25-35 times higher than MIC of SDS in the efflux null strain.  Cells 
producing TriAxBC were only marginally different in their susceptibility to SDS, in the 
presence of FhuA expression. The susceptibility of cells carrying the efflux null plasmid 
did not change in the presence or absence of FhuA.  Although for TriAxBC MICs of 
triclosan was at least two times less than that of cells producing TriABC, neither were 
affected by the expression (or lack thereof) of the engineered outer membrane pore. 
MIC of triclosan (TriABC+ and TriAxBC+ cells) were at least 16 time higher than the 
MIC in efflux null cells.  Yet again for the null cells in the presence or absence of 
FhuA, there was not a difference in MICs of triclosan.  Thus, TriABC and TriAxBC are 
functional in ∆9FhuA cells in the presence and absence of the FhuA pore. 
 SDS (µg/ml)  Triclosan (ng/ml) 
Variants 0% Arab 0.1% Arab   0% Arab 0.1% Arab 
 - 9 9  4 4 
AcrAB >2500 312  128 128 
TriABC >2500 312  >128 128 
TriAxBC >2500 156-312  64 64 
AR130DxBC 9 9  2-4 2 
AxBR118DC 312 78-156.6  64 32-64 
AG350CxBC >2500 156-312.5  128 128 
AxBG339CC 19 19  4 8 
 
Table 1.0.1 Antimicrobial Susceptibility of E. coli GKCW101 (∆9FhuA) Producing 
Plasmid Expressed TriAxBC Variants 
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1.2 Nile Red is the Best Probe for Kinetic Studies 
We next sought to identify a fluorescent probe, which could report on the efflux 
activity of the TriC transporter.  To investigate and establish the kinetic parameters of 
the pump in the ∆9FhuA background, we used the fluorescence probes Hoescht 33342 
(HT), n-phenyl-naphtylamide (NPN) and Nile Red (NR) in uptake assays to monitor 
real-time accumulation.  Fluorescence of Hoechst would be observed when the probe 
binds to the target, DNA, within the cell.  NPN and Nile Red are both highly fluorescent 
only when they bind to membrane lipids.  Working in E. coli, we used AcrAB alongside 
TriABC as a positive control for the pilot experiments using the Biotek Synergy H1 
Hybrid instrument to find optimal set up conditions for the assay.  All three fluorescent 
probes are known to be excellent substrates of AcrAB-TolC 72-74.  Briefly, harvested 
cells of OD600 ~2.0 were washed and resuspended in 50 mM KPO4
3-, 1 mM MgCl2, and 
0.4% glucose (PMG), and 100 µl of cells were added to equal volumes of two-fold 
dilutions of probes in PMG, formerly prepared in black microtiter plates.  NPN was 
excited at 356 nm and emission of light at 460 nm was recorded for 10 minutes (Figure 
1.0.3).  The same was done for HT and NR which were excited at 355 nm and 552 nm, 
respectively; emitted light at 460 nm and 636 nm, respectively, were recorded for 
analysis (Figure 1.0.4 and 5).  We found that uptake of the different fluorescence dyes 
led to different levels of accumulation within the cells; however, kinetic parameters 
could not be determined.  As expected, we note that with all three probes, the efflux 
proficient cells accumulated less fluorophore than the efflux deficient cells, as indicated 
by their fluorescence intensities.  Comparing the fluorescence intensities within the cells 
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after 10 minutes of exposure to probes (fourth panel of Figures 1.0.3-5), we find that 
NPN accumulation in ∆9FhuA (pTriABC) was twice less than efflux null cells unlike 
cells with AcrAB which reduced accumulation by 5 times (Figure 1.0.3). HT uptake in 
∆9FhuA (pTriABC) was similar to efflux null cells, indicating that HT is not a good 
substrate of TriABC.  However, ∆9FhuA (pAcrAB) was able to reduce uptake of HT by 
5 times (Figure 1.0.4).  In the case of Nile Red, TriABC producing cells decreased the 
amount of NR in the cells, similar to AcrAB efflux proficient cells (Figure 1.0.5).  Due 
to the comparable efficiencies of AcrAB and TriABC to reduce Nile Red accumulation 
in the cell, we used this probe for subsequent studies. 
 
1.3 Optimization of Cell Densities for Nile Red Uptake Assays 
In order to further optimize the assay and to increase the range of probe 
concentrations used in the assay, we repeated experiments with different cell densities 
(Figure 1.0.6).  In this experiment we used ∆9FhuA (pAcrAB) and ∆9FhuA (pBSPII).  

































































































































































































































































































































































































OD600 ~1.0 the signal was the highest but the difference in slopes of Nile Red uptake 
between efflux null cells and ∆9FhuA (pAcrAB) cells was the smallest. At OD600 ~0.1, 
efflux null cells showed a concentration dependent effect on emitted fluorescence, 
however, efflux proficient cells showed very low fluorescence signals.  Thus the use of 
cells at OD600 ~0.5 was the best – within the range of Nile Red concentrations used, 
both AcrAB and efflux null cells produced fluorescent intensities above background 
levels.  Cells at this optical density (OD600 ~0.5) was used for subsequent experiments. 
We confirmed the efficiency of AcrAB and TriABC in the ∆9FhuA cells to lower the 
accumulation of substrate. We also expressed the covalently linked TriAxB, with TriC, 
and found that is also effective in reducing of intracellular accumulation of Nile Red in 
the permeabilized cells (data not shown). 
 
1.4 There is No Competition Between Nile Red and Triclosan 
To investigate the effects of triclosan on NR accumulation and expulsion, we 
measured uptake of 4 µM Nile Red in the presence of increasing concentrations of 
triclosan.  We observed no difference in NR uptake even at concentrations 8 times 
Figure 1.0.6 Calibrating Nile Red Uptake Assay on the TECAN Spark 10M 
Cells were grown to OD600 >2.0, washed, then diluted in the phosphate, magnesium, 
glucose (PMG) buffer to OD600 ~0.2, 1.0 or 2.0. Equal volumes of cells and Nile Red 
were mixed and measured for analysis. Cell at 0.1 densities were not effective in 
showing uptake activities in AcrAB-expressed cells. At OD600 ~0.5, plus and minus 
efflux cells were better visualized, and more separated than at densities of 1.0.  The 




higher than the MIC of triclosan in efflux-null cells (4 ng/ml) (Figure 1.0.7). Results 
show that there is no competition between triclosan and NR at the binding pockets of 
TriC prior to efflux from the cells.  
 
1.5 TriA and TriB Have Non-Equivalent Roles in TriABC Functionality 
Previously, we used unique aspartic acid and cysteine mutations in the coiled-
coil and membrane proximal domains, respectively, of TriA and TriB to establish the 
roles of each MFP within the functional complex (Figure 1.0.1) 33.  Our results 
suggested that TriA is responsible for the recruitment of the OMP and stabilization of 
the tetrapartite complex, while TriB is responsible for the interactions with the 
transporter, TriC.  We employ the same mutants within this experiment to characterize 
how mutations in TriA and TriB within the complex affect efflux activity (Figure 1.0.8).  
MICs of triclosan and SDS in the ∆9FhuA cells confirmed the importance of TriAR130 
and TriBG339 in the TriABC complex (Table 1.0.1). Cells expressing these mutants were 
nonfunctional.  Comparing the analogous mutants in the partner MFP, TriAG350CxBC 
was fully functional.  However, TriAxBR118DC showed up to 4 times lower MICs of 
SDS in the presence and absence of the FhuA expression; triclosan MICs were the same 
Figure 1.0.7 Triclosan and Nile Red Do Not Compete for Uptake  
In the presence of 4 µM NR, a triclosan titration was used to test potential competition 
between substrate and probe.  2-fold concentration increases of triclosan, exceeding 
measured MIC of triclosan in efflux null cells, was not sufficient to cause notable 
changes in uptake of NR. 
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as wildtype TriAxBC.  Thus, we confirm the role of the conserved arginine in the TriA, 
but not TriB, coiled-coil domain for complex functionality. Similarly, we show that the 
membrane proximal mutation TriBG339C, but not TriAG350C, affects TriABC efflux 
proficiency. 
 
1.6 TriA, but not TriB, is Essential for TriABC Efflux of Nile Red 
To examine the effects of mutations on complex functionality in vivo, TriAxBC 
variants were used in NR uptake assays. We found that despite the differences between 
the TriAR130DxBC and TriAxBR118DC, as well as TriAG350CxBC and TriAxBG339CC 
mutants in MIC measurements, uptake experiments did not show results consistent with 
the MIC phenotypes.  In agreement with MIC measurements, TriAR130DxBC is defective 
in the efflux of fluorescence probe, Nile Red.  TriAxBG339C, however, did not follow the 
Figure 1.0.8 Nile Red Fluorescence and Rates of Uptake 
A. Final fluorescence of NR uptake after 10 minutes exposure to cells.  Efflux null cells 
increasingly acquire NR into the cell as NR concentrations increase.  TriAxBC and its 
functional variants show an ability to efflux NR, reducing amounts of dye within the 
cell.  The same was true for TriAxBG339CC, although MICs showed it to be functional, 
the cells were efficient in ridding itself of NR.  The non-functional mutant 
TriAR130DxBC, however, was less efficient in expelling NR thus showing increased 
fluorescence, though not the same as efflux null cells.  B. Initial rates of NR uptake into 
the cells were calculated using MATLAB. With increased NR concentrations, rates of 
uptake increased.  
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same patterns, but rather proved to efficiently efflux Nile Red as the wildtype TriAxBC 
and other functional mutants (Figure 1.0.8A). 
Data was fit using MATLAB, into the equation y=a1 + a2 (1 – e
-k2x), where a1 is 
the initial fluorescence intensity of NR, a2 is the intensity at the end of the desired range 
of activity, k2 is the rate of uptake, and x is the initial time.  Applying our data to this 
equation, this yielded initial rates of Nile Red uptake in ∆9FhuA cells expressing 
TriAxBC and its cysteine and aspartic acid variants.  In general, as the concentration of 
Nile Red increased so did the initial rates of uptake (AU/sec). The pattern of increase 
suggests that at higher concentrations of Nile Red the rates achieve saturation (Figure 
1.0.8B). As was observed with the uptake efficiency, the rates of uptake for cells 
expressing TriAxBR118DC, TriAG350CxBC and TriAxBG339CC were comparable to that of 
wildtype TriAxBC and AcrAB (Figure 1.0.8B).  Initial rates of NR uptake in cells 
expressing TriAR130DxBC were similar to that of efflux-null cells at low concentrations 
of NR.  However, at concentrations greater than 4 µM NR, the rates of Nile Red 
accumulation in ∆9FhuA (pTriAR130DxBC) cells reduced. 
Together, we find that TriA and TriB have different roles in the function of 
TriABC.  The α-helical domain of TriA, but not TriB, is essential for a functional 
complex.  Conversely, the membrane proximal domain of TriB, but not TriA, was 
essential for resistance to triclosan and SDS.  However, we found that the TriBG339C 
mutant of the MP domain, although non-functional in the expulsion of triclosan and 
SDS, showed activities similar to wildtype in the efflux of NR.  This result indicates 
that although a loss of function is observed in cells expressing this mutant, the assembly 
of the complex was not compromised.  Having shown the lack of competition between 
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triclosan and NR, we can conclude that the mechanism of NR efflux is different from 
that of triclosan though both molecules target cell membrane lipids. 
 
1.7 Association with TolC Changes TriA Conformation 
As described in Section 1.5, we established that the non-identical MFPs of 
TriABC assume different roles within the functional complex.  Co-purification results 
showed that mutations in the coiled-coil domains of TriA and mutations in the 
membrane proximal domain of TriB abolished interactions with the outer membrane 
channel protein, TolC 33.  Next, we sought to investigate the conformational state of the 
TriA/TriB proteins, in the presence and absence of the OMF.  For this purpose, we used 
in vivo proteolysis to highlight what is observed in the cells.  P. aeruginosa GKCW122, 
a strain lacking six major efflux pumps and with the cell wall permeabilized by the 
Figure 1.0.9 TriAB, TriABC, TriAxBC Expression in P. aeruginosa GKCW122 
Whole cell expression of 1e8 cfu cells.  Tri proteins were expressed in cells with 
permeabilized membranes. FhuA expression was dependent on 1 mM isopropyl β-D-
1-thiogalactopyranoside (IPTG) or 0.5% L-arabinose induction. Proteins were 
separated by SDS-PAGE and visualized by A.  anti-TriA and B. anti-TriB antibody 
serum. 
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cork-free FhuA protein, was transformed with TriAB, TriABC and TriAxBC from 
pBSPII plasmids (Figure 1.0.9). In both the independently expressed MFP constructs 
and the covalently linked variant, TriB showed a higher expression than the TriA 
counterpart (Figure 1.0.9). In preliminary experiments, we found that smaller amounts 
of proteins were present when TriAB was expressed in conjunction with FhuA 
production under isopropyl β-D-1-thiogalactopyranoside (IPTG) control versus the 
arabinose inducible FhuA expression. Therefore, we used the arabinose-inducible FhuA 
for pilot experiments.   
Cells were grown at 37°C until OD600 ~1.0, FhuA expression was induced with 
0.5% L-arabinose at OD600 ~0.3-0.5, and cells were harvested by centrifugation.  
Aliquots of cells were treated with trypsin at final concentrations of 0.1, 1.0, 10, and 50 
µg/ml.  Samples were separated by SDS-PAGE gel electrophoresis and visualized by 
anti-TriA/B immunoblotting (Figure 1.0.10).  In the absence of the TriC pump, TriA 
and TriB proteolytic fragments can be seen in samples treated with up to 10 µg/ml 
trypsin.  Although the amounts of unprocessed TriA and TriB decreased, no digested 
fragments were observed in samples treated with 50 µg/ml trypsin indicating a faster 
Figure 1.0.10 TriAB, ABC, and AxBC Proteolysis in P. aeruginosa GKCW122 
In vivo trypsin protease digest of Tri proteins in the presence of cork-free FhuA (under 
the arabinose promoter). 
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processing of the proteins into smaller fragments that cannot be detected.  There were 
no digestion fragments for either MFPs, in the presence of TriC (Figure 1.0.10).  This 
could be due to the lower expression levels of the proteins prior to digestion.  
Much like the TriAB construct, TriAxBC digested fragments were only evident 
in samples treated with 1 and 10 µg/ml trypsin.  Neither TriA nor TriB fragments were 
observed in 50 µg/ml trypsin although the amount of whole length TriAxBC decreased.  
In samples treated with 1 µg/ml trypsin, we note different digestion profiles of TriA and 
TriB from the covalently linked construct. TriA digestion showed traces of fragments 
smaller than the ~40 kDa, the relative size of the individual adapter proteins.  An 
experiment with 0.1 µg/ml trypsin further highlighted these bands (data not shown).  
The same digest profile was not observed for the TriB. 
In order to better cross examine the conformations of the TriAB proteins, when 
in assembly with TriC, the proteins were expressed in GKCW102 (∆tolC fhuA+) and 
GKCW104 (tolC+ fhuA+) (data not shown).  Proteins were expressed from pBAD33-
TriABC (± pBAD-TriCHis).  As previously discussed 
33, TriC expression is not observed 
in this background thus the pBAD-TriCHis was used to supplement production of the 
transporter protein when needed.  Using the above proteolysis protocol, in vivo TriAB 
digest was analyzed in the presence and absence of TriC and TolC.  Purified TriABC 
and TriAxBC proteins were also analyzed for comparison (Figure 1.0.11). Proteins were 
treated with 0.1, 1.0, and 10 µg/ml trypsin.  As shown on Figure 1.0.11A, TriA was 
susceptible to digestion by trypsin in the absence of TriC, regardless of the presence or 
absence of TolC (Figure 1.0.11A).  TriB, however, was protected from protease activity 
in either cases (Figure 1.0.11B). In the presence of the TriC pump, TriA digest was 
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partially protected when TolC was not present (Figure 1.0.11C). The opposite was true 
for TriB.  Though it was now subject to digest, unlike in the absence of TriC, the 
presence of TolC ever so slightly protected the protein from the effects of trypsin 
(Figure 1.0.11D).  
In vitro proteolysis of TriABC showed that TriA, but not TriB, was hydrolyzed 
(Figure 1.0.11A, B).  The same was true for the fused TriAxBC.  Treating the proteins 
with 1 µg/ml trypsin, TriA was showed more fragments in its profile while TriB did not 
show any digest small than ~40 kDa.  This is consistent with in the in vivo studies, 
proving that TriB has a different folding and conformation than its partner, protecting it 
from digest even in the TriAxB fused construct 
Figure 1.0.11 Proteolytic Profiles of TriAB  
Whole cells (GKCW102 and GKCW104) expressing TriAB and purified TriABC and 
AxBC were treated with increasing concentrations of trypsin.  TriA (A) and TriB (B) 
fragments were visualized by anti-TriA and anti-TriB antibody immunoblotting, 
respectively.  C. TriA and D. TriB fragments of GKCW102 and GKCW104 cells 
expressing TriABC were resolved by immunoblotting 
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AcrA Arg 128 is a conserved residue that affects the function of AcrAB-TolC 71. 
We introduced an aspartic acid mutant at the analogous positions in TriA and TriB 
(Figure 1.0.1), and found that the conserved amino acid in TriA but not TriB, is 
essential in the TriABC-TolC complex 33.  Using proteolysis, we wanted to find out the 
effects of the point mutation on the protein conformation in the presence and absence of 
TriC and TolC.  Using the same procedure as before, mutants were treated with trypsin 
in the presence and absence of OMF TolC. TriAR130D, co-expressed with TriB and TriC, 
was digested by trypsin when the channel protein was not expressed, more so than 
wildtype TriABC (Figure 1.0.12A, upper panel).  In the presence of TolC, increased 
trypsin concentration did not yield as many fragments as TriAR130DBC alone. This 
showed a protection of TriA by the TolC.  This avoidance of digestion was observed in 
the TriB proteins that were co-expressed with TriAR130D and TriC.  The expression, or 
lack thereof, of TolC did not change this TriB digest profile (Figure 1.0.12A, lower 
panel).  TriABR118DC showed similar results.  In the presence of TolC, TriA was still 
protected from digestion by trypsin (Figure 1.0.12B, upper panel). However, though it 
is vulnerable to processing, TriA in TriABR118DC showed a different profile than 
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wildtype TriABC.  TriB, in TriABR118DC, also shows less susceptibility to trypsin digest 
in the presence and absence of TolC (Figure 1.0.12B, lower panel).  Aside the change in 
profile of TriB in the presence of the TriAR130DBC and TriABR118DC coiled-coil mutants 
versus in the wildtype, the overall lack of difference in degradation profile further 
confirms that the TriB accessibility to trypsin is independent of the presence of TolC.  
Our results suggest that TriA interactions with TolC change the MFP conformation – 
digestion profiles changed in the presence or absence of TolC.  However, TriB 
conformations did not change in the presence or absence of the channel protein. 
In the similar experiments with the point mutations in the membrane proximal 
domains – TriAG350CBC and TriABG339CC – we find that once again the overall digest 
profile of TriA and TriB differed one from the other.  In experiments with cells 
expressing TriAG350CBC-TolC, TriA was highly susceptible to protease cleavage 
(Figure 1.0.13A, upper panel) but TriB was not as sensitive (Figure 1.0.13A, lower 
Figure 1.0.12 Proteolytic Profiles of TriAB in Aspartic Acid Variants of the Coiled-
Coil Domain 
A. TriA and TriB fragments of TolC plus and minus cells producing TriAR130D mutants.  
B. Same as A for cells producing TriBR118D mutants 
 
56 
panel).  Without the TolC channel protein, TriA and TriB were both less sensitive to 
cleavage (Figure 1.0.13A).  In cells expressing TriABG339CC-TolC, TriA was slightly 
less susceptible to protease than wildtype (Figure 1.0.13B, upper panel).  Without TolC, 
however, the TriA proteolytic profile was the same as wildtype.  TriB was the same as 
the wildtype, even in the absence of TolC (Figure 1.0.13B, lower panel).  Once again 
we note that the TriB protein, which is more essential for interactions with the 
transporter TriC, is subject to trypsin digest regardless of TolC expression.  The 
exception was with TriAG350CBC expression without TolC.  TriA, however, was 
affected by the presence or absence of TolC (Figure 1.0.13B, upper panel).  Also, the 
digest profiles were different in the essential and non-essential mutant backgrounds, 
indicating different conformations of TriA.  
Taken together, we show that TriA and TriB proteins assume independent, non-
equivalent roles within the bacterial cell.  The α-helical domain of TriA helps stabilize 
Figure 1.0.13 Proteolytic Profiles of TriAB in Cysteine Variants of the Membrane 
Proximal Domain 
A. TriA and TriB fragments of TolC plus and minus cells producing TriAG350C mutants.  
B. Same as A for cells producing TriBG339C mutants 
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interactions with the OMP, while the TriB membrane proximal stabilizes interactions 
with TriC.  TriA proves to be important in the complex activity – as seen from the MIC 
measurements and efflux of Nile Red.  However, we find that although the essential 
amino acid in TriA (TriAR130) changes complex functionality, it does not affect 
assembly – rates of NR uptake were lower that efflux null cells, indicating the presence 
of an assembled, partially active complex in the cell.  Protease digest results also 
differentiate the MFPs.  TriA and TriB differ in conformations, however, the TriA 
protein changes conformation in the presence and absence of TolC.  This data supports 
the role of TriA as the stabilizer of the complex with the OMP, but also presents this 
protein as the one responsible for the recruitment of the OMF protein. 
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Chapter 2. Investigation of TriAB Interactions and Mechanism of 
Opening the Channel Protein 
The unique TriABC-OpmH efflux pump of Pseudomonas aeruginosa provides a 
powerful model by which mechanisms of efflux pumps can be studied.  Unlike 
previously studied efflux pump systems, there are two different MFPs in this complex 
33, 49.  As we described above, TriA and TriB have two distinct roles within the complex 
with TolC (Figure 2.0.1) and its P. aeruginosa homolog OpmH. TriA is essential for 
stabilization of the complex and interactions with TolC/OpmH, while TriB is important 
for interactions with the transporter, TriC 33.  In either cases, we had yet to assign the 
interfaces of OMF-MFP or MFP-IMP interactions.  In this study, we used disulfide 
bonding to position TriA and TriB on OpmH, as would be seen in the functional 
complex.  Aside showing a symmetric arrangement of the MFPs in complex, we assign 
the TriB protein the responsibility of the opening of the outer membrane protein, 
OpmH. 
 
2.1 OpmH is an Essential Protein of Efflux-Deficient P. aeruginosa.  
TriABC-OpmH efflux complex is functional in the strain PAO1116 (ΔmexAΒ-
oprM ΔmexCD-oprJ ΔmexEF-oprN ΔmexJK ΔmexXY ΔtriABC) lacking six efflux 
pumps 33.  The deleted triABC genes were supplemented by the expression of the 
proteins from a plasmid, in order to complement the chromosomally expressed OpmH.  
In order to purify and identify the OMF protein, a 6-Histidine tag was added to the 
OpmH protein sequence. At the same time, we sought to move the opmH gene into a 
different position on the chromosome and bring it under a promoter control (Section 
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II.1.1).  We used the attTn7 site for insertion onto the chromosome and brought the 
opmH gene under control of the arabinose-inducible promoter.  In this process, we 
found that deletion of the original opmH could not be achieved lest we have the second 
copy integrated at the attTn7 site.  As shown on Figure 2.0.2, the P. aeruginosa JWW9 
Figure 2.0.1 TolC Crystal Structure 
The trimeric TolC crystal structure (PDB code: 1EK9) with the corresponding 
OpmH Glu 173 and Lys 183 mutation of loop 1, and Ile 392 and Val 396 of the 
inclined helices marked in varying colors.  Labeled mutations are the correlating 
amino acids in the TolC structure. 
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strain produced OpmHHis upon induction with L-arabinose and the protein production 
was dependent on the concentration of arabinose used (Figure 2.0.2).  
Overnight cultures of JWW9 cells with plasmid encoded TriABC or the 
covalently linked TriAxBC 33 in LB with 100 µg/ml carbenicillin and 1% L-arabinose 
were washed and reinoculated into fresh  LB supplemented with 100 µg/ml 
carbenicillin, and varying amounts of arabinose and allowed to grow.  After 5 hours of 
incubation cells were used to test the antibiotic susceptibility, as well as to check the 
amount of protein production.  We found that MICs of triclosan and SDS increased as 
arabinose concentrations increased (Table 2.0.1).  However, MICs for SDS reached a 
plateau at 0.1% arabinose, while that of triclosan plateaued at 0.5% arabinose. Under 
the same conditions, whole cells and membrane fractions were examined by 
immunoblotting with anti-His antibodies (Figure 2.0.2).  In the whole cell, OpmHHis 
was not detected until 0.5% arabinose was used to protein expression (Figure 2.0.2A).  
In the membrane fractions, however, the expression of OpmH depended on whether or 
not TriABC was also present (Figure 2.0.2B). When OpmH was expressed alone, 
Figure 2.0.2 Arabinose Concentration-Dependent OpmH Expression 
Overnight cultures of OpmH cells were reinoculated in varying concentrations of LB-
arabinose and allowed to grow to OD600 ~1.0.  A. 1x10
8 cfu of whole cells and B. 100 
ng of membranes were separated by SDS-PAGE electrophoresis. Samples were 




0.01% arabinose was sufficient to see the protein.  In the presence of TriABC or 
TriAxBC, traces of OpmH was first detected upon induction with 0.1% arabinose.  
Considering the overall levels of OpmH was lower, it could be reasoned that the 
presence of TriABC regulates the amount of OpmH present within the cell. 
 
2.2 OpmH Cysteine Variants Are Functional and Assemble into Complexes with 
TriABC 
To identify and study the OMF-MFP interface interactions, we introduced 
unique cysteines into the OpmH proteins. Sites subjected to the mutagenesis were based 
on computational analysis using the GREMLIN web server 75, 76. OpmH amino acid 
residues Glu 173, Lys 182, Ile 392, and Val 396 (Figure 2.0.1) were predicted to 
interact with certain TriA and TriB side chain residues at probabilities greater than 90%. 
Like the wildtype protein, OpmH cysteine variants were not easily integrated onto the 
chromosome at the attTn7 site lest the original gene was first present then deleted after 
successful insertion of the mutant. We introduced cysteine mutations pTJ1-opmH. PCR 
and sequencing were performed to confirm the native opmH gene had been deleted and 
that the opmH cysteine mutant gene was present under the control of the arabinose 
promoter.  DNA sequencing showed that aside OpmHV396C, integration of the cysteine 
SDS Triclosan SDS Triclosan SDS Triclosan SDS Triclosan SDS Triclosan
pBSPII 19 2-4 19 4 78 16 312 32 312 32
pBSPII-ABC 312-625 16-32 625-1250 16-32 2500+ 32 >2500 64 >2500 64
pBSPII-AxBC 312 16 625 16 >2500 32 >2500 >128 >2500 >128
0.01% Arab 0.1% Arab 0.5% Arab 1.0% Arab0% Arab
Table 2.0.1 Arabinose-Dependent Antimicrobial Susceptibility of P. aeruginosa 
JWW9 (PAO1116 attTn7::ParaBAD-opmHHis) Producing Indicated Tri 
Complexes. 
(SDS and Triclosan concentrations are in µg/ml) 
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OpmH variants was successful. OpmHV396C proved to be the wildtype OpmH without 
the intended cysteine mutation.  In fact, it was the only construct which continually 
evaded selection post mating; we repeatedly selected for the wildtype/OpmHV396C 
diploid or a wildtype OpmH at the attTn7 site. Thus we concluded that OpmHV396C is a 
non-functional mutant.  Since OpmH is essential for the cell, wildtype OpmH could not 
be deleted off the chromosome and replaced by a non-functional construct.  This also 
indicates the importance of the Val 396 amino acid for a functional TriABC-OpmH 
complex.  
We next analyzed the functional phenotype of the remaining mutants by 
measuring MICs of triclosan and SDS and found that all cysteine variants showed the 
same phenotype as wildtype OpmH (Table 2.0.2).   
 null  TriABC  TriAxBC 
Variants SDS  Triclosan   SDS  Triclosan    SDS  Triclosan  
OpmH  156.6-312.5  16-32   >2500  >128   >2500  >128 
OpmHE173C  156.6  32   >2500  >128   >2500  >128 
OpmHK182C  156.6  16   >2500  >128   >2500  >128 
OpmHI392C  156.6  16   >2500  >128   >2500  >128 
Table 2.0.2 Antimicrobial Susceptibility of JWW9 (OpmHHis) Cysteine Variants 
Containing the Plasmid Encoded TriABC 
(SDS and Triclosan concentrations are in µg/ml) 
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Using co-purification studies, we determined whether the OpmH-Cys mutants 
assemble the complete TriABC-OpmH complex.  For this purpose, OpmHHis and its 
cysteine variants were co-expressed with the plasmid-borne TriABC or TriAxBC. We 
purified OpmHHis using Cu-NTA affinity chromatography and equal amounts of 
wildtype and mutant proteins were separated by SDS-PAGE gel electrophoresis.  
We found that TriA, TriB, and TriC were all copurified with wildtype OpmH 
and its cysteine variants.  Amounts of protein pulled down were fairly equivalent, save 
the OpmHE173C mutant which more strongly bound TriABC and TriAxBC (Figure 
2.0.3). Located at the tip of the first loop (α-helices 3 and 4) of OpmH, with its amino 
acid side chain facing the interprotomer groove, the higher levels of TriABC association 
with OpmHE173C foreshadows a highly stable complex formation with this mutant. Thus, 
substitution at the interprotomer groove is important for the complex stabilization as 
H3-H4 interacts with the TriA/TriB membrane fusion proteins. 
Figure 2.0.3 OpmH Cysteine Variants Assemble in Complex with TriABC 
Immunoblotting analysis of 100 ng OpmHHis variants (shown by silver staining) 
purified from cells producing TriABC or TriAxBC complexes. Co-purification of 
TriA, TriB, and TriC with OpmHHis (W), OpmHE173C-His (E), OpmHK182C-His (K), or 
OpmHI392C-His (I), were detected by immunoblotting with anti-TriA, anti-TriB, and 
anti-TriC antibodies respectively. 
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2.3 TriA and TriB Cysteine Variants Are Expressed and Functional 
Based on the Gremlin web server analysis, three TriA and three TriB amino acid 
residues were identified as putative interacting partners of OpmH at the sites discussed 
above (Figure 2.0.4).  In TriA, Ala 134, Lys 138, and Gly 139 were predicted to interact 
with the OpmH residues at greater than 90% probability.  The equivalent TriB residues 
are Glu 122, Arg 126, and Ser 127.  All six of these residues are found at either the 
Figure 2.0.5 TriA and TriB Cysteine Variants Are Expressed 
Immunoblotting analysis of membrane fractions isolated from JWW9 cells producing 
indicated TriABC complexes and their variants. 100 ng of total membrane proteins 
were separated by SDS-PAGE and analyzed by immunoblotting with anti-TriA or 
anti-TriC antibodies.   
Figure 2.0.4 TriA and TriB Cysteine Mutants 
Modeled structures of TriA (A) and TriB (B) based on the crystal structure of MexA 
(PDB code: 2V4D) with highlighted amino acids used in crosslinking studies.  Residues 
were based on Gremlin web server analysis, and the equivalent mutants in TriA and 
TriB are noted in the same color. 
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higher end of the coiled-coil domain of the MFPs or in the loop between the two α-
helical segments (Figure 2.0.4). 
Using site directed mutagenesis, we introduced the desired cysteine residues into 
the covalently linked  TriAxB 33 per the manufacturer’s manual.  Using isolated cell 
membranes, protein expression was assessed.  We found that TriAxBC mutants were 
expressed at similar levels as the wildtype (Figure 2.0.5). Once again, we analyzed the 
phenotypic effects of the engineered cysteines on the complex functionality. We found 
that none of the mutants affected the cell’s susceptibility to SDS or triclosan (Table 
2.0.3).  
Using the results of the AcrΑ-TolC crosslinking studies 23, we engineered two 
more cysteine residues to test the specificity of protein-protein interactions within the 
complex. TriAA116CxB and TriAxBA104C, located midway of the first coiled-coil helix of 
the respective MFP, as well as TriAE145CxB and TriAxBR133C, positioned nearby the tip 
of the coiled-coil domains were used as controls (Figure 2.0.4).  All control mutants 












Table 2.0.3 TriAxBC Cysteine-Containing Mutants Are Functional 
Relative antimicrobial susceptibility of P. aeruginosa JWW9 (OpmHHis) producing 
TriAxBC cysteine variants with mutations in the coiled coil domain 
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were expressed (data not shown) and fully functional compared to the wildtype (Table 
2.0.3).   
 
2.4 OpmHE173C, OpmHK182C, and OpmHI392C Form Disulfide Bonds with Both TriA 
and TriB 
 We next sought to determine and assemble there OpmH-TriA/B interface 
interactions.  We co-expressed OpmH cysteine variants, on the chromosome, with each 
of the TriA and TriB cysteine mutants (expressed from plasmids) to observe 
spontaneous disulfide bonding.  Equal amounts of total membrane proteins were 
analyzed by SDS-PAGE gel electrophoresis and visualized by immunoblotting using 
anti-TriB or anti-His antibody serum to visualize (Figure 2.0.6).  
Figure 2.0.6 TriAxBC and OpmH Cysteine Mutants Form Spontaneous Disulfide 
Wildtype OpmH and OpmHI392C were individually co-expressed with pTriAxBC 
cysteine mutants. One set of cells was pretreated with NEM prior to cell lysis. 10 µg of 
membrane proteins were separated by SDS-PAGE and immunoblotting was used to 
identify protein bands.  Cross-examining anti-TriB (A) and anti-His (B) immunoblots 
confirmed disulfide formation between cysteines. 
 
In the subsequent experiments, all cells were treated with 5 mM NEM and incubated for 
5 minutes.  We were better able to identify high molecular bands with the His-tagged 
OpmH.  Superimposing the results of crosslinking visualized with anti-TriB and anti-
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His antibodies, we found that the high molecular band seen in the anti-His westerns are 
also present in the anti-TriB gels, confirming the complex formation of TriAxB with 
OpmH (data not shown).  Cysteine pairs that showed spontaneous disulfide formation  
were further analyzed for potential toxicity to the cell as well as for the effects on the 
cell’s susceptibility to triclosan and SDS.  Results show that disulfide formation does 
not affect the functionality of the TriAxBC-OpmH efflux pump (Table 2.0.4). 
Immunoblotting analysis of the full set of TriA/B mutants – the predicted 
positions, as well as the chosen controls – interacting with OpmH showed that 
Figure 2.0.7 OpmH Cysteine Variants Form Bonds with Both TriA and TriB 
Cysteine variants of TriA and TriB were co-expressed with OpmH cysteine strains in 
the presence of 1% L-arabinose. Pretreated with 5 mM NEM, cell membranes were 
harvested and 10 µg of total membrane proteins were separated by SDS-PAGE 
electrophoresis. Immunoblotting with anti-TriB and anti-His antibodies show binding of 
OpmH mutants to both MFPs of the efflux complex. 
SDS Triclosan 
OpmH - pBSPII 312.5 16-32
OpmH - pBSPII-AxBC >2500 >128
OpmHE173C : pBSPII-AK138CxBC >2500 >128
OpmHI392C : pBSPII-AA134CxBC >2500 >128
OpmHI392C : pBSPII-AxBR126CC >2500 >128
Table 2.0.4 MICs of Select OpmH Cysteine Mutants Co-Expressed with 
TriAxBC Cysteine Variants 
(SDS and Triclosan concentrations are in µg/ml) 
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OpmHE173C, OpmHK182C, and OpmHI392C formed disulfide bonds to both the TriA and 
TriB proteins at the correlating positions (Figure 2.0.7).  As shown on Figure 2.0.6, the 
mobility of TriΑ-OpmH differed from that of TriΒ-OpmH.  Using the results of three 
independent experiments, we quantified the intensities of visualized bands from the 
anti-His developed immunoblots (Figure 2.0.8).  Determining the ratios of TriA/B 
bound to OpmH, we assigned the preferred MFP mutant at each OpmH cysteine 
location (Table 2.0.5).   
OpmHE173C showed preferred binding to TriA, the most significant (greater than 
95% confidence level) with TriAA134CxBC and TriAE145CxBC.  These mutants showed 
preferred interactions with OpmHE173C 2 and 3 times, respectively, more than 
A-A116C 1.36 B-A104C 1.48 B-A104C 1.04
A-A134C 2.08* B-E122C 1.12 A-A134C 1.52
B-R126C 1.12 B-R126C 1.16 B-R126C 2.06
A-G139C 1.29 B-S127C 1.90* B-S127C 1.49**
A-E145C 3.01* A-E145C 1.29 A-E145C 4.17*
OpmH E173C OpmH K182C OpmH I392C
Table 2.0.5 OpmH Cysteines Show Preference for TriABC Bonding 
*p-Value <0.05 **p-Value <0.1 
 
Figure 2.0.8 Quantified of TriAxB-OpmH Disulfide Bonding 
Immunoblot results of three independent spontaneous disulfide bond formation 
experiments were compiled and analyzed.  Anti-His westerns were scanned and bands 
were quantified using BioRad’s Quantity One. 
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complexes with analogous cysteine substitutions in TriB.  OpmHK182C favored binding 
to TriB, but most significantly with TriAxBS127CC which was twice more favored than 
the corresponding mutant in TriA (TriAG139CxBC).  OpmHI392C did not show a clear 
inclination of binding to TriA or TriB, however, the most significant pairing came from 
the control position at TriA Glu 145.  Of the predicted amino acid sites, TriB Ser 127 
showed significant binding to OpmHI392C, but it was within 90% confidence (Table 
2.0.5). 
Based on these results, we can conclude that OpmHE173 which is located on the 
H3-H4 pair of the OMF exclusively prefers interactions with TriA.  Facing the 
intraprotomer groove of the protein, OpmHK182C also has a strong preference to TriB of 
the TriAxB construct.  However, located on the second, dynamic helical loop of OpmH, 
and also facing the intraprotomer groove, we find that Ile 392 can interact with either 
TriA or TriB.  Putting these together, we find that although the TriAxΒ-OpmH complex 
can assemble in a symmetric fashion, as would be expected, it is also capable of 
Figure 2.0.9 TriAB-OpmH Assembly Models 
A. TriAB assembled in the expected, symmetrical arrangement about the outer 
membrane protein, OpmH. B.  Based on our crosslinking studies, at least one inter-
protomer groove is occupied by TriB thus presenting an asymmetric assembly of 
proteins. 
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arranging itself asymmetrically (Figure 2.0.9).  However, due to the non-equivalent 
roles of TriA and TriB, as well as the covalently linked TriAxB, the asymmetric 
assembly is unlikely. 
 
2.5 TriB Opens the OpmH Channel Aperture 
Salt bridge interactions at the periplasmic end of OMFs have been found to 
render these channel proteins closed in the resting state 7.  Based on the structure 
similarities to TolC, we conclude that in the case of OpmH there is also a dilation of the 
α-helices of the periplasmic barrel to open the protein for substrate extrusion 77 (Figure 
2.0.10).  To test this, we analyzed the cysteine mutants of TriA and TriB in pairs with 
OpmH cysteines in azithromycin susceptibility assays.  Bacterial lawns of cells with 
combinations of cysteine mutants were spotted with azithromycin and grown overnight.  
If mutations in the plasmid-borne TriAB dilate the periplasmic aperture of OpmH, 










Figure 2.0.10 Closed and Open Conformations of the TolC Periplasmic Aperture 
Bottom view of the outer membrane channel protein.  The α-helices of loop 1 (H3 and 
H4) and lop 2 (H7 and H8) are indicated in both structural conformations.  
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wildtype OpmH-wildtype TriABC interactions.  We used azithromycin instead of 
vancomycin because the parental PAO1116 strain is sensitive to the macrolide 
azithromycin but is resistant to vancomycin (unpublished data).  Zones of inhibition 
were measured in mm and the averages of three independent experiments are reported 
(Figure 2.0.11). We used wildtype OpmH in combination with the TriA or TriB 
cysteine mutants as well as the combinations of OpmHCys with the TriAxB mutants. 
Further analysis of the results by t-tests determined the significance of measured zones, 
comparing all samples to the wildtype TriAxBC-OpmH combination. 
We found that of the TriAxB cysteine mutants, TriAG139C had a significantly 
decreased zone of inhibition of azithromycin compared to the wildtype pair.  When 
expressed in conjunction with OpmHE173C, we found that TriAxBR126C allowed the cell 
to increase its susceptibility to azithromycin.  In the case of OpmHK182C, it was the 
control mutant TriAxBR133C that showed an increased cell resistance to the drug. Unlike 
Figure 2.0.11 TriB is Essential for Opening the OpmH Channel Protein 
Zones of inhibition on bacterial lawns, expressing the double cysteine mutants, spotted 
with1.25 µg of azithromycin were measured and reported. TriB mutants proved more 
capable of opening the OpmH channel. OpmHI392C showed significant opening of 
channel and increased susceptibility to drug in the presence of three different TriB 
cysteine mutants, indicating the role and placement of the MFP in a functional TriABC-
OpmH complex. 
*p-Value <0.05 (A total of 8 zones were used for analysis.) 
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the other two cysteine positions, OpmHI392C was very biased to the three predicted 
amino acid positions of TriB (TriBE122, TriBR126, and TriBS127).  These OpmHI392C -
TriBCys interactions were significant, and showed increased zones of azithromycin 
inhibition. 
In the crosslinking studies we found that OpmHE173C, of the interprotomer 
groove, has a bias for TriA association, however, we find that in this experiment it was 
the TriBR126C that showed significant interactions.  The correlation of OpmHK182C, 
which faces the intraprotomer groove, having significant interactions with TriB held 
true in this experiment.  We also found a strong and consistent preference of OpmHI392C 
interactions and effects in the presence of TriB cysteine mutants.  It can be said that 
though OpmHI392C can interact with both MFPs, it is the interactions of TriB in the 
interprotomer groove of OpmH that allows for the opening of the OpmH aperture.  Thus 
the association of TriA in this H4-H8 groove, as seen in the previous experiment, is a 
transient interaction.  Previously, we determined the role of TriB as being essential in its 
interactions with transporter TriC for a functional complex 33.  Coupling that with these 
findings, we can further reason that the relay of conformational changes within the TriC 
protein allows the TriB protein to engage and open the OpmH aperture.  TriA remains 
the anchor and stabilizer of the complex, not significantly playing a role in the opening 
of the channel to allow extrusion of substrates. 
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Altogether, we find that OpmH is an essential protein of the cell, which cannot 
be removed or replaced, even with a non-functional variant.  Mapping the distal α-barrel 
of OpmH and the loops of TriAB with unique cysteines, we determined that TriA and 
TriB can both occupy the inter- and intraprotomer grooves of the channel protein.  
Despite the evidence from crosslinking studies pointing to potential asymmetric 
assembly of the TriAB proteins around OpmH, the non-equivalent roles of the proteins 
weaken this hypothesis and suggests a symmetric assembly of TriAB in the hexameric 







































































Figure 2.0.12 Proposed Mechanism of OMP Aperture Opening 
TriB initially recruits and docks on the OMP OpmH.  TriA undergoes conformational 
changes to bind OpmH and stabilize the complex.  Stimulation of TriC, by TriB, caused 
the opening of the periplasmic aperture as substrate is expelled against proton influx. 
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stabilizes the complex with OpmH.  Specifically, TriA interacts with OpmH at the 
interprotomer grooves, aligned to the “static” helices of the α-barrel.  Thus TriB is 
mostly found in the intraprotomer groove.  In the intraprotomer groove, TriB interacts 
with the dynamic helices of OpmH to render the aperture open for substrate expulsion.  
We propose that in the mechanism of substrate efflux by TriABC, TriB recruits and 
engages OpmH in complex.  TriA undergoes a conformational change to associate with 
the OMP and stabilize the complex while TriB stimulates the transporter TriC and 
opens the periplasmic aperture for substrate extrusion (Figure 2.0.12).  
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Chapter 3. Structural Analysis of the TriABC Complex 
 Thus far, genetic manipulations in TriABC-OpmH have been based on the 
AcrAB-TolC complex.  The broadly studied AcrAB-TolC has presented many 
structural and biochemical insights of each protein, as well as complexes of the 
partnering proteins.  In order to verify that the structures of TriABC-OpmH follow this 
model, we purified individually expressed proteins, as well as protein complexes, to 
determine protein and complex structures for this unique RND pump system. In 
collaborations with the Jurgen Sygusch and Isabelle Rouiller labs, we used small angle 
x-ray scattering (SAXS) and negative staining EM, respectively, to analyze the 
structures of TriC, TriAxBC and TriAxBC-OpmH. 
 
3.1 The Open Conformation of TriAxBC Complex 
3.1.1 TriABC Form a Stable Complex 
Purified proteins were prepared as described in Methods.  Proteins were of about 
90-95% purity, yielding varying concentrations of proteins from 1 L cultures (Figure 
3.0.1).  To better identify the TriA and TriB proteins within complex, we introduced 
unique cysteines in the α-helical domains of TriA (Glu 145) and TriB (Arg 133), both in 
Figure 3.0.1 TriAxBC-OpmH Protein Purification 
Equal volumes of purified proteins in elution buffer collected from the Cu-NTA affinity 
columns were analyzed by 10% SDS-PAGE gels. Fractions of proteins were eluted in 
50 mM Tris-HCl (pH 8.0) buffer, 150mM NaCl, 0.03% n-Dodecyl β-D-
Maltopyranoside (DDM), 1 mM phenylmethylsulfonyl fluoride (PMSF), and 400mM 
Imidazole. All samples were visualized by Coomassie Blue Staining. 
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the stabilized, covalently link TriAxB construct, and labeled with nanoprobe for 
structural analysis.  We found that the wildtype TriAxB and its cysteine variants form 
stable complexes in solution with the transporter, TriC (Figure 3.0.1). 
 
3.1.2 RND TriC is Dynamic in Solution 
TriC in solution was found to be a homogeneous trimer.  TriC particles (Figure 
3.0.2A) were analyzed and found to resemble the E. coli AcrB, having the three 
domains characteristic for RND transporters (Figure 3.0.2B).  Results also show that 
TriC is dynamic in solution.  One conformation illustrated what would be the inner 
cavity between the protein trimers (Figure 3.0.2B).   
 
3.1.3 TriA and TriB Assume Different Conformations in Solution. 
Images of the TriAxBC complex illustrated features unique to the complex.  
Unlike the MacA protein which was crystallized and shown to form a hexameric tunnel 
Figure 3.0.2 Homotrimeric TriC Protein Structure 
A. Negative staining EM of TriC. Boxes represent TriC particles that are seen and used 
for analysis.  B. Five different TriC structure constructions, showing the i. docking 
domain (red triangle), ii. the pore domain with cavities that allude to binding pockets, 
and iii. the transmembrane domain (green dotted line). The structure show that TriC is 
dynamic outside of the cell membrane.  One construction (1) shows the inner cavity 
through the protein, but all constructions (1-5) show different measurements between 
the transmembrane domains (red arrow). 
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47, the α-helices of TriAB are not shown to assemble in this rigid structure. Three α-
helical pairs of TriAB were found to be in a folded conformation, one on top of the 
other (Figure 3.0.3A).  This structure was found to rest on the docking and pore 
domains of the TriC protein (Figure 3.0.3C).  In order to resolve the identity and 
placement of the MFPs, unique cysteines were engineered – TriAE145CxBC and 
TriAxBR133CC – and labeled each with NANOGOLD® particles.  Briefly, purified 
proteins were incubated with tris(2-carboxyethyl)phosphine (TCEP) to reduce disulfide 
bonds.  Recovered protein was mixed with freshly prepared NANOGOLD® in 2 molar 
excess and incubated at room temperature for 2 hours.  Excess gold was removed by 
using Nap™-5 Sephadex™ G-25 DNA Grade columns (GE Healthcare).  Labeled 
TriAxBR133CC proved successful in allowing the visualization of the α-helices that could 
not be identified otherwise.  However, localization of gold in nine different regions of 
the reconstituted structure (Figure 3.0.3B) did not allow us to isolate the MFP identities 
Figure 3.0.3 TriABC Structure Predictions  
A. TriABC construction from samples, superimposed onto the TriC (yellow) EM map. 
TriAB are seen collapsed about what would be the pore and docking domains of TriC.  
B. Gold particles of labeled TriBR133C are localized in 9 different regions. C. Docking of 
a TriABC model (cartoon representation) unto the projected EM map. 
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within the folded conformation.  SAXS results are in agreement with the negative stain 
EM imaging of TriAxBC, as seen in these experiments (data not shown).  Also, low 
yields and lack of homogeneity of purified TriAxBC-OpmH in solution resulted in a 
lack of any structural models for the complex. 
 
3.2 TriAxBR133CC Maintains Wildtype Protein Conformations  
To confirm the use of the NANOGOLD®-labeled TriAxBR133CC is 
representative of the wildtype TriAxBC structure, purified proteins were subject to 
trypsin protease digests.  Briefly, equal amounts of protein were treated with 0.1, 1.0, or 
10 µg/ml trypsin and incubated at 25° C for 1 hour.  Samples were mixed with sample 
buffer, without a reducing agent, boiled and separated by SDS-PAGE.  Protein bands 
were visualized by silver staining (Figure 3.0.4).  1 µg/ml trypsin with wildtype 
Figure 3.0.4 Gold-Labeled TriAxBC Has Same Conformation as the Wildtype 
Purified proteins were treated with trypsin showed no observable difference between 
wildtype and mutant.  Crosslinked with sulfosuccinimidyl 6-(3’-(2-
pyridyldithio)propionamido)hexanoate (LC-SPDP) prior to proteolysis, TriAxBR133CC-
LS, again did not suggest a different conformation than the wildtype. 
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TriAxBC produced several major bands indicating the truncation of the protein, likely 
into the individual monomers.  The digestion profile of TriAxBR133CC was identical to 
that of the wildtype.  To test if we could induce and lock the TriAxBR133CC mutant with 
disulfide bonds, to help with the structural caveats from SAXS and negative staining 
EM, TriAxBR133CC purified proteins were treated with sulfosuccinimidyl 6-(3’-(2-
pyridyldithio)propionamido)hexanoate (LC-SPDP) prior to trypsin digest. There was no 
observable difference between the wildtype and mutant proteins (Figure 3.0.4).  Neither 
was there a change in profile compared to the non-crosslinked samples.  Thus resolved 
structural conformations from this mutant were a good representation of wildtype 
TriAB. 
In conclusion, we show that the TriABC proteins are stable in solution and share 
structural similarities to homologous proteins of their respective families. TriC 
assembles into a homotrimer, resembling the structure of AcrB.  Though the TriAB 
fusion proteins fold like MexA in predictive models, this study shows that in the 
absence of TolC the two proteins do not maintain the funnel-like structure of the α-
helical domain and assume different conformations, as was seen in our proteolysis 
studies (in a previous chapter).  Nonetheless, we see that the TriAB dimers dock unto 
TriC, as has been seen in AcrAB complex models, thus results show that TriABC-
OpmH assembles into a complex representative of RND efflux proteins  
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Chapter 4. Assessment of AcrΑ-TolC Interactions by Fluorescence 
Spectroscopy 
 The constitutively expressed Resistance Nodulation Division (RND) efflux 
pump complex of Escherichia coli, AcrAΒ-TolC, is one of the most studied tripartite 
systems.  AcrB is an inner membrane transporter protein. A proton antiporter, AcrB 
provides the energy needed for the complex functionality. TolC is an outer membrane 
factor (OMF) providing a tunnel exit for substrate extrusion across the asymmetric 
bacterial cell wall into the extracellular space. Interacting with these two proteins in the 
periplasm is the membrane fusion protein (MFP), AcrA.  In this study we sought to 
reconstitute the assembly of AcrAΒ-TolC tripartite complex in vitro by investigating 
the interactions at the AcrΑ-TolC interface; we used fluorescence spectroscopy as our 
tool of studies.  Using pyrene maleimide, we expect an excited pyrene molecule, in 
close proximities with an unexcited pyrene, to form an excimer which emits 
fluorescence at a higher wavelength (~470 nm) than the excited monomeric pyrene 
(~375-395 nm) 70 
 
4.1 Development of Fluorescence Assay 
We introduced unique cysteine residues in AcrA and TolC using site-directed 
mutagenesis (Figure 4.0.1).  The trimeric TolC protein has three major domains – the β–
barrel which spans the outer membrane, the α–barrel domain which extends deep into 
the periplasmic space, and the equatorial domain which is midway around the α–barrel. 
At the extracellular side, between the beta sheets of the β–barrel are two asymmetric, 
flexible loops; we engineered a mutant on the larger of the two loops, TolCA269C (Figure 
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4.0.1B). Granted each protomer of the α–barrel is made up of two sets of a continuous 
and semi-continuous coiled strand pairs, one pair is inclined 20° towards the core of the 
periplasmic opening. The outward-facing TolC Lys 383 was shown to interact with 
AcrA Asp 149 23, thus we used this amino acid in our studies. We also used TolCQ142C, 
located at the outer tip of the “straight” strand pairs, to check the specificity of TolC 
interactions with AcrA (Figure 4.0.1B). Lastly, aside the constriction created at the 
periplasmic end of the TolC barrel by the inclined helical pairs, there is a second 
bottleneck for substrates created by the networking of Asp 374 of the three monomers.  
We introduced the same mutations of wildtype TolC and its “open”, TolCYFRE variant. 
YFRE is a double-substituted TolC mutant, Tyr 363 to Phe and Arg 367 to Glu, to 
disrupt the salt bridge and hydrogen bond networking in the bottleneck of the 
periplasmic tunnel of TolC, leaving the protein opening ajar 61.  We used 
Figure 4.0.1 AcrA and TolC Protein Structures 
A. Crystal structure of AcrA based on MexA (PDB code: 2V4D), model was generated 
using Phyre2 web portal 4. Asp 149 (purple) is located in the α-helical domain of the 
protein while Gly 363 (magenta) is in the flexible membrane proximal domain. B. The 
trimeric TolC crystal structure (PDB code: 1EK9) with the (magenta) Q142C, A269C, 
D374C, and (purple) K383C mutations.  
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TolC/YFRED374C as another means of detecting the efficiency of pyrene labeling and 
detection of ring stacking.  Unlike the TriAB-OpmH studies, we would characterize the 
interactions at the MFP-OMP interface as well as the integrity of these interactions 
within the dynamic complex. 
The periplasmic membrane fusion protein, AcrA, is made up of the four 
domains – the α-hairpin, lipoyl, β-barrel, and membrane proximal domains (Figure 
4.0.1A) 20, 22. Although the overall structure is flexible, thanks to the short linker 
regions, the membrane proximal domain has proved to be the most unsteady. The 
highly flexible construction is shown in the crystal structure of AcrA, which excludes 
this fourth domain 22. We used AcrA Asp 149 of the coiled-coil region and Gly 363 in 
the membrane proximal domain (Figure 4.0.1A) as site for mutagenesis.  AcrAD149C was 
found to interact with TolC in a crosslinking study 23.  AcrAG363C has been shown to be 
essential for the functional activity of AcrAΒ-TolC 48.  It was later shown that the 
purified AcrAG363C was better able to retain interactions with AcrB and TolC than 
wildtype AcrA in the surface plasmon resonance (SPR) assays 44. 
Table 4.0.1 Antimicrobial Susceptibility of E. coli ZK769 Cells Expressing TolC 
and YFRE. 
Substrate  
MIC (µg/mL)  
pTrc  TolC  TolCK383C  YFRE  YFREK383C  
Puromycin  2 64 64 32 32 
Chloramphenicol  0.8 3.2 3.2 3.2 3.2 
Erythromycin  1 64 64 16 16 
Novobiocin  1 32 32 16 16 
SDS  9.76 >10,000  >10,000  >10,000 >10,000 
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Figure 4.0.2 AcrA and TolC Cysteine Mutant Expression and Protein Purification 
A. Whole cells (5e+07 cells) expressing AcrA and TolC cysteine mutants were analyzed 
by SDS-PAGE electrophoresis followed by transfer onto a PVDF membrane and 
incubation with anti-His, anti-AcrA, or anti-TolC antibodies. All mutants are expressed 
to the similar levels as was the wildtype.  B. Equal volumes of purified proteins in elution 
buffer collected from the Cu-NTA affinity columns were analyzed by 10% SDS-PAGE 
gels. Fractions of AcrA were eluted in 20 mM Tris-HCl (pH 8.0) buffer, 500mM NaCl, 
0.03% n-Dodecyl β-D-Maltopyranoside (DDM), 1 mM phenylmethylsulfonyl fluoride 
(PMSF), and 500mM Imidazole. The TolC proteins were eluted in 20 mM Tris-HCl (pH 
7.5) buffer, 100mM NaCl, 0.03% (DDM), 1 mM (PMSF), and 500mM Imidazole.  All 
samples were visualized by Coomassie Blue Staining. 
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4.1.1 Expression, Functionality, and Purification  
Isolated cell membranes visualized by immunoblotting showed that expression 
of the mutants AcrA and TolC were similar to that of the wildtype proteins (Figure 
4.0.2A). The effects of the cysteine mutations in TolC on its function was tested by 
measuring the MICs.  We found that the Lys 383 to Cys mutation in TolC does not 
affect the susceptibility of cells to antibiotic substrates (Table 4.0.1).  
For the in vitro studies, wildtype proteins and cysteine variants were 
overexpressed by induction with isopropyl β-D-1-thiogalactopyranoside (IPTG), under 
the lac operon. The 6-histidine tagged proteins were bound and eluted off Cu-NTA 
affinity chromatography columns.  AcrA was eluted in 20 mM Tris-HCl (pH 8.0) 
buffer, 500mM NaCl, 0.03% n-Dodecyl β-D-Maltopyranoside (DDM), 1 mM 
phenylmethylsulfonyl fluoride (PMSF), and 500mM Imidazole. TolC proteins were 
eluted in the same buffer (pH 7.5), except 100 mM NaCl was used.  Elution fractions 
were separated by SDS-PAGE and visualized by Coomassie Brilliant Blue staining 
(Figure 4.0.2B).  All proteins were at least 90% pure. 
 
4.1.2 Fluorescence Assays with Free Pyrene Maleimide 
 The honeycomb-shaped pyrene modified with a maleimide group addition 
(Figure 4.0.3A) allows for more selectivity in reactions with thiol groups and eliminates 
cross-reaction with histidine and methionine 78. Previously, it has been reported that in 
organic solvents, as the concentration of pyrene is increased, the expected decrease in 
monomer fluorescence was replaced by a unique quenching. This quenching occurs 
when an excited pyrene molecule, in close proximities with an unexcited pyrene, forms 
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an excimer which emits fluorescence at 470 nm 70.  To determine fluorescence intensity 
emitted by pyrene, when excited with light at 337 nm, we varied the amount of sample 
exposure to light by using different bandwidth openings (data not shown). We also 
investigated the effects of buffer pH on fluorescence activity. We found that at 5 nm 
bandwidth, there was an increase in fluorescence intensity as buffer pH was increased 
from 5.0 to 7.5 (Figure 4.0.3B).  Using the same specifications, we then investigated the 
concentration-dependent of pyrene fluorescence intensities in buffer pH 7.5.  
Fluorescence intensities increase as the concentration of pyrene increased (Figure 
4.0.3C). 
 
4.1.3 Pyrene Maleimide Labeling and Fluorescence Assays 
In order to label the purified AcrAD149C and TolCK383C proteins with pyrene, the 
thiol groups were reduced in the presence of tris(2-carboxyethyl)phosphine (TCEP) 
resin, then incubated with fresh pyrene maleimide (Figure 4.0.3A) in 20 molar excess. 
Excess pyrene was removed and proteins were dialyzed into the buffer containing 20 
mM MES (pH 6.0), 0.03% DDM and 150 mM NaCl for experiments. 
Figure 4.0.3 Fluorescence Spectrum of Pyrene Maleimide 
A. The honeycomb-shaped pyrene molecule modified with a maleimide group.  B. 
Emission spectrum of 20 µg/mL (67.3 µM) pyrene maleimide (PM) at varying pH 
buffer conditions.  PM was excited at 337 nm and the intensities were measured through 
a 5 nm bandwidth. C. Concentration-dependence fluorescence of free PM in 20 mM 
Tris-HCl (pH 7.5), 150 mM NaCl, 0.03% DDM.  Experiments were done at room 
temperature with 5 nm bandwidths. 
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To find optimal experimental conditions, the emission spectra between 360-560 
nm of the individually labeled proteins were collected at different protein 
concentrations.  We also mixed AcrΑ and TolC in varying ratios and measured 
fluorescence intensities. However, no red-shift peaks, as would be expected for 
AcrAD149C and TolCK383C interaction, were detected (data not shown). 
We calculated the ratios of PM present in the protein samples by defining the 
area of fluorescence intensities then determining the amount of fluorescence intensities 
between 375-395 nm, and we compare the values to a calibration curve of free PM 
fluorescence intensities (data not shown). Results show that there was excess PM in the 
protein samples. Therefore, we tested alternate ways of labeling the proteins (Figure 
4.0.4A). In addition to reducing protein samples in TCEP resin, we prepared two 
additional samples: one batch was reduced by 50 mM dithiolthreitol (DTT), the excess 
Figure 4.0.4 Alternate Labeling of AcrAD149C with Pyrene Maleimide 
A. Three aliquots of purified AcrAD149C were subject to different reducing conditions 
prior to labeling with PM.  Two sample sets were subject to TCEP resin or 50 mM 
TCEP. The third sample aliquot was reduced by 50 mM DTT and subject to gel 
filtration prior to PM labeling. All three protein sets were then labeled with 10 molar 
excess PM, dialyzed to remove excess PM from the reaction, then used in experiments. 
B. Emission spectrum of AcrAD149C-PM excited at 337 nm, bandwidth of 5 nm, and in 
20 mM MES (pH 6.0), 150 mM NaCl, and 0.03% DDM. 
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of which was removed by Nap™-5 Sephadex™ G-25 DNA Grade columns (GE 
Healthcare).  The other batch was reduced by addition of 50 mM TCEP solution to 
reduce disulfide bonds. All three sets of sample preparation were labeled with 10 molar 
excess PM instead of 20 molar excess.  The excess pyrene was removed by Nap™-5 
Sephadex™ G-25 DNA Grade columns, all samples were dialyzed and used for 
experiments.  Fluorescence emission spectrum (Figure 4.0.4B) and calculations of PM-
AcrA ratios, showed that at pH 6.0 AcrAD149C incubation within TCEP resin was the 
best reducing and labeling procedure, granted there was still excess PM in relation to 
amount to AcrA (data not shown). 
Despite the fact that AcrΑ-TolC binding interactions has been proven at pH ~6.0 
44, we did not see any indication of protein-protein interactions by expected red-shift 
fluorescence peak at ~470 nm.  We tested proteins labeled by different protocols, as 
well as the fluorescence emission pattern of AcrΑ-TolC at higher pH (pH 7.5) and with 
a smaller bandwidth (3 nm) for light entrance and exit. At this pH, the AcrA and TolC 
proteins retain their positive and negative charges, respectively. Prior to experiments, 
we investigated the appropriate means of labeling each protein and found that 
AcrAD149C was most efficiently labeled with PM under non-reducing conditions, 
TolCK383C was best labeled after reduction of thiols in TCEP resin, and YFREK383C was 
best labeled when thiols were reduced in 50 mM TCEP (Figure 4.0.5). 
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4.1.4 Time Course Analysis of AcrΑ-TolC Interactions  
 Hypothesizing that reaction time in the established fluorescence assay was not 
enough to observe what could be a transient reaction, we sought to investigate the effect 
of time.  We set up our experiments the same as before: we analyzed individually 
labeled proteins, as well as mixed labeled AcrAD149C and TolCK383C.  Emission 
intensities were measured at 465 nm every 20 seconds for 10 minutes. Results showed 
no observable difference of all reactions (data not shown). 
 
4.2 Optimizing Fluorescence Assay for AcrΑ-TolC Interaction Studies 
4.2.1 Stabilizing Protein-Protein Interactions by pH and Mg2+  
SPR studies of AcrΑ-TolC 25 showed that the protein-protein interactions were 
best investigated at pH 6.0. We initially performed experiments of AcrAD149C and 
TolCK383C under these conditions but there were no observed protein-protein interactions 
by an excimer peak formation on the fluorescence spectrum (Figure 4.0.6A, C). To 
Figure 4.0.5 Concentration-Dependent Fluorescence Spectrum of PM Labeled 
AcrAD149C, TolCK383C, and YFREK383C. 
Samples were in 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 0.03% DDM, excited at 
337 nm, with bandwidths of 3 nm. Protein samples were treated in various ways prior to 
PM labeling, the best methods are shown. A. AcrAD149C thiols were not reduced prior to 
PM labeling, B. TolCK383C was reduced in TCEP resin, and C. YFREK383C was best 
labeled after reduction by 50 mM TCEP, with no dialysis before labeling. 
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promote more stable protein-protein interactions, producing more stable pyrene 
stacking, AcrΑ-TolC samples were supplemented with Mg2+. 
It has been shown that the presence of Mg2+ does not change conformations of 
proteins, but it is able to affect protein stability 79.  Titrating AcrA and TolC, in buffer 
conditions of pH 6.0, we also added 1 mM Mg2+ to produce more stable protein 
interactions. Fluorescence emission spectrum of both experiments proved futile (Figure 
Figure 4.0.6 AcrAD149C-TolCK383C Do Not Interact at pH 6.0 
In combination studies of AcrAD149C and TolCK383C, labeled purified proteins were 
mixed at ratios indicated and used for experiments.  All samples were in 20mM MES 
(pH 6.0), 150 mM NaCl, and 0.03% DDM. Pyrene was excited at 337 nm, and 
bandwidths were set at 3 nm.  Titrating AcrAD149C to TolCK383C (A), we did not see any 
peaks for excimer formation so 1 mM MgCl2 (B) was used to stabilize potential 
interactions. We also titrated TolCK383C to AcrAD149C in the absence (C) and presence 
(D) of Mg2+. We again did not observe red shift peaks at 470 nm to indicate protein-
protein interactions.  
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4.0.6B, D), there was not any indication of pyrene-pyrene stacking under these 
conditions. 
Exploring the effects of buffer condition on ionic strengths and protein 
interactions, we increased buffer pH conditions to 7.5 where AcrA was less positively 
charged and TolC proteins were more negatively charged (Figure 4.0.7A). Repeating 
the AcrAD149C-TolCK383C protein pair interaction studies, we titrated AcrA amounts to 
TolC and induced interactions by supplementing the reaction buffer with 1 mM Mg2+ 
(Figure 4.0.7B) and did not obverse changes in the emission spectrum. Increasing 
Figure 4.0.7 Mg2+ Stabilizes AcrAD149C-TolCK383C Interactions at pH 7.5 
A. Titrating pyrene labeled AcrAD149C to TolCK383C in 20 mM Tris-HCl (pH 7.5), 150 
mM NaCl, and 0.03% DDM, the fluorescence spectra of pyrene emission did not show 
interactions between the proteins. B. Stabilizing interactions with 1 mM MgCl2 had no 
effect. C. Increasing Mg2+ concentration to 5 mM produced a second peak in the 
fluorescence spectrum.  D. The same result was not observed for AcrAD149C with 
YFREK383C. 
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induction to 5 mM Mg2+ proved effective; we saw a new peak in our results at ~490 nm 
(Figure 4.0.7C). Investigating the consistency of the AcrAD149C-TolCK383C interactions, 
as would be found in the cell, we used the open, YFREK383C, TolC. Using the same 
experimental conditions, we found that interactions of AcrAD149C-YFREK383C were not 
stabilized in the presence of 5 mM Mg2+ (Figure 4.0.7D).  Results were not 
reproducible.  
 
4.2.2 Reselection of Amino Acids  
The experiments described above inferred that the chosen sites were not close 
enough for the monitoring of interactions by fluorescence spectroscopy using pyrene 
maleimide.  In order to further prove the effectiveness of PM for labeling and as a probe 
for studying protein-protein interactions, we selected different amino acid residues in 
AcrA and TolC.  For AcrA, we used AcrAG363C, an amino acid residue in the membrane 
proximal domain (Figure 4.0.1A).  For TolC/YFRE we mutated Ala 269 of the 
extracellular loops, and Gln 142 and Asp 374 of the α-barrel domain (Figure 4.0.1B).  
When labeled with pyrene at these positions, the proteins were to induce pyrene-pyrene 
stacking more readily.  We did not see excimer formation in any of these experiments 
(data not shown). 
 
4.2.3 Inducing Disulfide Bonding 
 The trimeric TolC periplasmic aperture is interlocked by hydrogen bonds and 
salt bridges involving the interactions the amino acid residues Thr 152, Asp 153, Tyr 
362, and Arg 367 37. This ~4 Å opening is the first of two bottlenecks of the TolC 
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structure. The second, tighter bottleneck is found higher up in the α-barrel domain, and 
consists of three Asp 374 – one from each monomer of TolC 62.  Considering that such a 
constriction might not allow for effective labeling of pyrene maleimide at Asp 374, we 
checked all mutants for spontaneous disulfide formations. 
 Purified AcrA and TolC cysteine variants were labeled with PM per earlier 
established protocols. 150 ng of boiled protein was separated by 10% SDS-PAGE gel 
electrophoresis, in the absence of reducing agents, and visualized by silver staining 
(Figure 4.0.8).  We found that except for TolCK383C and YFREK383C, all other mutants 
formed oligomers in the presence and absence of pyrene.  This result was inconsistent  
with the fluorescence spectra which did not show the red shift characteristic in the case 
of AcrAD149C, AcrAG363C, TolC/YFREA269C, and TolC/YFRED374C.  
Figure 4.0.8 TolC/YFREK383C Does Not Form Spontaneous Disulfides 
150 ng of boiled pyrene labeled or free protein samples were separated by 10% SDS-





 Since we see dimerization on the gels but not by fluorescence, we tested whether 
AcrAD149C and TolC/YFREK383C could form disulfide bonds by gel electrophoresis. To 
help promote disulfide bonding between the two cysteine modified proteins, we 
incubated proteins with 50 µM CuCl2 after reducing thiols in the presence of TCEP. In 
the absence of reducing agents, we found that we were able to induce disulfide bond in 
TolCK383C and YFREK383C samples containing Cu
2+ (Figure 4.0.9A, B). Titrating AcrA 
and TolC/YFRE in the presence of Cu2+, we were able to identify high molecular 
weight oligomers.  Treating these samples with DTT, we found that the observed 
oligomers were not AcrΑ-TolC interactions – the protein profiles were the same as seen 
before (Figure 4.0.9C, D).  
Figure 4.0.9 AcrAD149C-TolC/YFREK383C Interactions Cannot Be Stabilized by Cu2+ 
Purified protein samples were treated with 5 µM TCEP for 1 hour. Mixed protein 
combinations (A - AcrAD149C-TolCK383C, B - AcrAD149C-YFREK383C) were oxidized with 
50 µM CuCl2 for 30 minutes to promote disulfide bonding. Samples were boiled and 
separated by 10% SDS-PAGE gel electrophoresis and visualized using silver staining. 
Samples were treated with DTT (C, D) to reduce high molecular weight samples. We 
did not note a difference in protein profiles in the presence of DTT. 
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 Taken together, we find that despite the previous results showing interactions of 
AcrAD149C and TolCK383C 
23, we could not reproduce said interactions nor could we 
determine the integrity of said interactions with the closed and open TolC 
conformations. Considering experiments with alternate sites of protein labeling did not 
produce results as expected, we can deduce that conditions are not sensitive enough to 
map the protein-protein interfaces of the AcrΑ-TolC bipartite complex.  However, 
experiments with TriAB-OpmH (see previous chapters) indicate that docking of AcrA-
TolC, as being studied (wrapping), is different from the preferred mode of assembly 
(bridging) of MFPs and OMFs.  Nonetheless, pyrene maleimide labeling and analysis of 
excimer formations was not sufficient to characterize interactions within protein 
protomers.  
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Chapter 5. Surface Plasmon Resonance Studies of EPI Interactions 
with Transporter Protein AcrB 
There have been strategies proposed and used for the disabling of functional 
efflux pumps within the bacterial cell 18. In this study, we explore one such strategy, the 
use of efflux pump inhibitors (EPIs).  These inhibitors are designed to be used in 
addition to therapeutics to reduce the minimal inhibitory concentrations (MICs) of 
antibiotics, however, it has also been shown to reduce the invasiveness of human 
pathogens, such as Pseudomonas aeruginosa 80.  
Figure 5.0.1 Phenylalanine Arginyl β-





In collaboration with Basilea Pharmaceutica, we sought to identify EPIs that 
would interact with the transporter AcrB.  For this purpose, we used SPR to analyze the 
binding kinetics of EPIs to immobilized AcrA, AcrB, and TolC.  Phenylalanine arginyl 
β-napthylamide (PAβN) is the first compound identified as an EPI effective against the 
Pseudomonas MexAB pump (Figure 5.0.1).  It has been shown to restore activities of 
antibiotics of different classes 81, 82. However, although PAβN has also been shown to 
compete with certain antibiotics – imipenem and gentamicin– it does not compete with 
the likes of levofloxacin and carbenicillin 82-84.  PAβN inhibits efflux by causing an 
accumulation of pump substrates within the cell, as well as altering the permeability of 
the P. aeruginosa outer membrane.  We used PAβN as the control for our studies. 
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Basilea Pharmaceuitica discovered inhibitors (Table 5.0.1) were the analytes of interest 
for our experiments.  
Table 5.0.1 Basilea Pharmaceutica Efflux Inhibitors and Properties. 






1 2 3 4 
BAL 0113299-000-001 A3299 480.65 480.65 -5.00 4.94 9.21 -5.59 
BAL 0113347-001-001 B3347 316.82 389.75 -5.16 7.89 10.60  
BAL 0113468-001-001 C3468 424.51 652.55 6.57 10.19 -5.36 -1.83 
BAL 0113470-000-001 D3470 308.29 308.29 2.85 -7.17 15.36 -8.32 
BAL 0113501-001-001 E3501 483.53 597.55 5.13 -6.40 -5.34 -1.83 
BAL 005718-002-002 F5718       
BAL 0108043-001-001 J8043 312.45 385.37 -5.18 9.89 7.11  
BAL 0113594-001-001 K13594 395.72 468.64 -5.16 7.89 10.60  
BAL 0113711-001-001 L13711 249.74 363.76 15.86 8.12 10.66  
BAL 0113731-000-001 M13731 336.14 336.14 -8.13 1.24   
BAL 0113758-001-001 N13758 282.34 355.26 -9.29 7.77 10.58  
 
To characterize the interactions of the compounds with the AcrB, we used 
Surface Plasmon Resonance (SPR).  SPR is a real-time binding assay that uses changes 
Figure 5.0.2 Surface Plasmon Resonance (SPR) 
SPR is a real-time binding assay that uses changes in the refractive index of light at 
the interface of a gold thin film on glass and solution of interest to measure the 
association and dissociation of biomolecules 6 
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in the refractive index of light at the interface of a gold thin film on glass and solution 
of interest to measure the association and dissociation of biomolecules 85 (Figure 5.0.2).  
SPR allows for the study of interactions of proteins, nucleic acids, cells, etc with 
binding partners as well as small molecules, even those in organic solvents; these 
interactions can be studied without labeling of binding partners. Another advantage of 
SPR, is the low volumes needed to run experiments and yet, due to the high sensitivity 
of the method, detection of interactions allows for kinetic and thermodynamic analysis, 
concentration assays, binding stoichiometries, etc.  In this study, experiments were 
conducted on 1. the SensíQ® Pioneer, with data analyzed using Qdat©, and 2. the 
Biacore 3000 unit, with data analyzed using the BIAEvaluation 2.1©. Previously, a 
similar approach had been used to characterize interaction of substrates and inhibitor 
with AcrB and to study protein-protein interaction of TolC and different MFPs 25, 44.  
Figure 5.0.3 SPR Chip Surface Chemistry for Protein Immobilization 
A. Biotinylated ligand is injected over the streptavidin surface of the chip to form 
an irreversible. B. In the chemistry of thiol coupling, the reduced thiol of the 
ligand substitutes the aromatic ring of the 2-(2-pryidinyldithio)ethaneamine 
(PDEA) in the final step.  
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To immobilize our proteins of interest (AcrB, AcrA, and TolC) to the 
streptavidin surface of the sensor chip, proteins were biotinylated before injection 
(Figure 5.0.3A). However, due to the irreversible nature of this bond, we later 
immobilized the proteins using thiol coupling (Figure 5.0.3B) to allow control of the 
amount of protein on the chip surface. Preliminary experiments were conducted on the 
SensíQ® Pioneer, then later simultaneously with experiments on the Biacore 3000. 
 
5.1 Immobilization of AcrB and AcrBD408A and Binding Assay Development on the 
SensíQ® Pioneer  
Previously, the AcrB protein had been genetically modified to replace the two 
intrinsic cysteine residues, at positions 493 and 887, to serines to create a cysteineless 
protein 44. This cysteineless AcrB was further modified by site-directed mutagenesis to 
Figure 5.0.4 AcrA, AcrB, and TolC Cysteine Variants for SPR Immobilization 
A. Crystal structure of AcrAS363C based on MexA (PDB code: 2V4D), model was 
generated using Phyre2 web portal 4. B. AcrBS1043C (purple) and the D408A mutant 
(magenta) (PDB code: 2HRT). C. TolC crystal structure (PDB code: 1EK9) with the 
A269C mutation.  
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introduce a cysteine at Ser 1043 (Figure 5.0.4B) to serve as the amino acid residue for 
the immobilization of the protein. Additionally, four histidine residues were introduced 
to the C-terminus of AcrB to create a 6-Histidine tag that was used for the purification 
of the proteins by Cu-NTA affinity chromatography 32.  
In the functional mechanism of AcrB, it has been shown that Asp 407, Asp 408, 
and Lys 940 are at the core of the proton translocation site, and the interactions and 
relay of a proton is responsible for the functional rotation of the transporter protein. The 
two negatively charged aspartic acid residues are responsible for the binding and release 
of the protons and thus are crucial for the binding and extrusion of drug substrates 3, 39, 
40, 86. We substituted the charged aspartic acid amino acid with a neutral alanine residue 
by site-directed mutagenesis (Figure 5.0.4B). The expression of AcrBD408A was the 
same as the wildtype protein (Figure 5.0.5A), but the mutation makes the protein non-
functional and thus was used to investigate the effects of function disruption on 
substrate binding specificity and efficiency with AcrB. 
Figure 5.0.5 Expression and Purification of AcrA, AcrB and TolC Mutants 
A. 2µg of unboiled AcrB and AcrBD408A were separated by 10% SDS-PAGE and 
transferred onto a PVDF membrane and incubated with anti-His antibodies. AcrBD408A 
expresses to the same level was the wildtype. B – E. Solubilized membranes in buffer 
containing 2% DDM was passed through Cu-NTA affinity column to bind Histidine-
tagged proteins. Non-specific interactions were disrupted by wash steps, then 
AcrAS362C, AcrBS1043C, AcrBS1043C-D408A, and TolCA269C proteins were eluted off separate 
columns in Tris-HCl buffer solutions, supplemented with NaCl, PMSF, DDM, and 
Imidazole. Elution fractions were separated by 10% SDS-PAGE and visualized by 
Coomassie Brilliant Blue staining. 
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To develop a binding assay, purified AcrBS1043C and non-functional AcrBS1043C-
D408A proteins (Figure 5.0.5C, D) were reduced in the presence of tris(2-
carboxyethyl)phosphine (TCEP) and immobilized onto the chemically-modified chip 
surface at approximately the same surface densities of 15898 Response Unit 87 and 
11197 RU, respectively (Figure 5.0.6). Wildtype AcrA was injected over the AcrB 
surfaces to validate that immobilization of protein by thiol coupling was successful, and 
to ensure that the proteins were still functional and interacting as formerly established 
44. We found that AcrA binds to the AcrB protein and its AcrBD408A variant with the 
Figure 5.0.6 Immobilization Sensogram of AcrB and mutant using Thiol Coupling 
All surfaces of gold chip undergo the same surface chemistry with the exception of 
protein of interest (or the control surface). AcrB and AcrBD408A bound with surface 
densities of ~16000 RU and ~11000 RU, respectively. 
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same affinity (Figure 5.0.7). Thus, both variants of the protein are competent in 
interaction with AcrA. 
Figure 5.0.7 AcrB and Mutant Bind AcrA with Similar Affinities 
Two-fold dilutions of wildtype AcrA (62.5 nM – 2 µM) was injected over the control, 
wildtype AcrB (A) and AcrBD408A (B) surfaces of the COOH5 chip. Protein samples 
in 20 mM MES (6.0), 150 mM NaCl, and 0.03% DDM were injected at 50 µl/min for 
2 minutes (association phase) and then stopped for 2 minutes (dissociation phase). 







































































































































































































































































5.2 Immobilized AcrB and Its Non-Functional Mutant Bind EPIs. 
AcrB functions as a trimer with two binding pockets per monomer.  The distal 
binding pocket has a phenylalanine-rich region that binds low-molecular-weight drugs 
and a proximal binding pocket and vestibule which binds larger compounds 88, 89.  To 
determine whether the immobilized AcrB variants were capable of binding the 
inhibitors and further compare the affinities, two fold dilutions of inhibitors were 
injected over the AcrB surfaces and the control surface in 20 mM MES running buffer 
(pH 6.0) supplemented with 150 mM NaCl, 0.03% DDM, and 5% DMSO (solvent for 
the small molecules). 
Table 5.0.2 Kinetic Parameters of Basilea EPI Binding to AcrB and Mutant 
Equilibrium constants represent the ratio of the dissociation and association rate 
constants.  Data was analyzed using Scatchard plots 
 
 KD (µM) 
AcrB AcrBD408A 
PAβN 625 625 
A3299 N/A N/A 
B3347 714 833 
C3468 N/A N/A 
D3470 76.9 64.5 
E3501 303 196 
  
Out of nine EPIs, 5 bound the immobilized AcrB.  The binding of B3347 had 
the greatest responses, implying that it may have multiple binding sites on AcrB. The 
binding curves of B3347 reached steady-state, as was seen with PAβN, within the one-
minute injection time (Figure 5.0.8A, C). The binding curves of A3299 and E3501 also 
reached steady-state within the experimental parameters, but at higher concentrations 
they showed a decrease in signal, possibly due to non-specific effects (Figure 5.0.8B, 
F).  
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Despite the inactivation of AcrB protein functionality with the D408A mutation, 
the mutant AcrB was able to bind the small molecules with comparable affinities to that 
of wildtype AcrB (Table 5.0.2), indicating that this inactivation does not affect substrate 
binding interactions with the binding pockets of AcrB.  The small difference of binding 
response units and affinities could be accounted to the difference of AcrB immobilized 
to the chip surface. 
 
5.3 Binding Affinities of EPIs Are Dependent on the Amount of AcrB Present. 
 The amount of AcrB within the E. coli cell was reported to be ~500 copies, 
compared to AcrA’s 5000-7000 copies, and TolC’s ~1500 copies 32. In our experiments, 
we tested the effect of AcrB and substrate binding and kinetics. Using thiol coupling, 
we immobilized wildtype AcrB on two surfaces of the sensor chip; surface densities of 
immobilized proteins was 4706 RU for the low density surface, and 6523 RU for the 
high density surface. Several substrates were used in experiments, and the kinetic 























































































































































































































Affinity constants of PAβN, A3299, B3468, and D3470 were determined by the 
negative reciprocal of the plot slopes (Figure 5.0.9Α-D).  Except D3470, the 
micromolar equilibrium constants correlated with the corresponding surface density of  
AcrB (Table 5.0.3).  As compared to the previous sensor chip with even higher AcrB on 
the surface, E3501 showed characteristics of negative cooperativity interactions with 
AcrB at these lower densities of immobilization (Figure 5.0.9E).  This suggested that 
binding of the substrate to AcrB decreases the binding of more substrate in another 
active site. The same relationship of binding interactions was seen for L13711 and 
N13758 (Figure 5.0.9H, I). For J8043 and K13594, we observed binding that indicated 
strong positive cooperativity interactions, both reaching saturation at ~0.625 mM of 
substrate. 
Table 5.0.3 AcrΒ-Dependent Substrate Binding Affinities 
Equilibrium constants of substrate binding is dependent on the amount of AcrB present.  
AcrB (low), ~4700 RU, and AcrB (high), ~6500 RU, were immobilized by thiol 
coupling on the SensíQ® Pioneer.  Data was analyzed using Scatchard plots. 
 KD (µM) 
AcrB (low) AcrB (high) 
PAβN 294 417 
A3299 1000 1429 
B3347 625 714 
D3470 1000 476 
   
 
5.4 Immobilization of AcrA, AcrB and TolC on the Biacore 3000. 
 The Biacore 3000 unit is a widely used instrument for studying kinetic 
interactions of biological molecules and structures alike. The sensor chip variations for 
the Biacore 3000 are comparable to that of the SensíQ® Pioneer, however, one major 
advantage is the availability of an extra surface which is also independently accessed 
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for immobilization and experiments. Taking advantage of this, we sought to check the 
specificity of substrate interactions with AcrB. To do this, we immobilized AcrAS362C 
and TolCA269C, alongside AcrBS1043C, to orient the proteins in the position of interest for 
protein-substrate studies (Figure 5.0.4, 5). We used thiol coupling, as discussed before, 
and attained 2308 RU for AcrA, 12216 RU for AcrB, and 2399 RU for TolC on the 
sensor surfaces. Per the Biacore manual, 100 RU of response on the CM5 chip is 
equivalent to 1mg/ml bulk concentration.  Therefore, we immobilized ~500 µM AcrA, 
~1000 µM AcrB, and ~450 µM TolC. We validated the integrity of the immobilized 
proteins by injecting PAβN on the AcrA, AcrB, and TolC protein surfaces.  There was 
concentration-dependent substrate binding with acrA and AcrB, but not TolC (data not 
shown). After this, we proceeded to characterize substrate binding kinetics. 
 
5.5 Basilea EPIs Bind More Specifically to AcrB than to AcrA or TolC 
 We tested the specificity of binding by the Basilea inhibitors to AcrB by 
checking binding interactions with AcrA and TolC, alike. We injected increasing 
concentrations of substrate on each protein surface and analyzed the sensograms, as 
corrected with the control surface (Figure 5.0.10). Despite the 1 AcrA:2 AcrB:1 TolC 
ratios of protein immobilization, the binding responses of the substrates do not reflect 
the same ratios. We observed that there was some binding of A3299, B3347, F5718, 
L13711 and N13758 to AcrA (Figure 5.0.11) and TolC (Figure 5.0.12), however, the 
binding curves varied in shapes for the substrate-protein pairs.  Analysis of the binding 
responses with respect to substrate concentrations showed that these produced 3-10 
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times more binding responses to AcrB than to AcrA or TolC (data not shown). J8043 
binding responses to  
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Figure 5.0.10 Inhibitors Bind AcrA 
Sensograms of two-fold dilutions of A. A3299, B. B3347, C. F5718, D. J8043, E. 
L13711, and F. N13758, injected over AcrA (2308 RU) in MES running buffer 
(pH 6.0) supplemented with NaCl, DDM, and DMSO. 
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AcrB was 10-40 times higher than that of TolC; there was no binding to AcrA (Figure 
Figure 5.0.11 Inhibitors Bind AcrB 
Sensograms of two-fold dilutions of A. A3299, B. B3347, C. F5718, D. J8043, E. 
L13711, and F. N13758, injected over AcrB (12216 RU) in MES running buffer (pH 
6.0) supplemented with NaCl, DDM, and DMSO. 
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5.0.10D, 11D, 12D). 
Figure 5.0.12 Inhibitors Bind TolC 
Sensograms of two-fold dilutions of A. A3299, B. B3347, C. F5718, D. J8043, E. 
L13711, and F. N13758, injected over TolC (2399 RU) in MES running buffer (pH 
6.0) supplemented with NaCl, DDM, and DMSO. 
 
112 
5.6 AcrΒ-Inhibitor Interactions Model a Bivalent Analyte or Two-State Model 
We fit the binding curves to kinetic models in the BIAEvaluation software such 
as the 1:1 binding model, sequential binding model, and two-state model (TS).  Global 
fittings are used to model and fit multiple fold-dilution injections of the same analyte 
(Figure 5.0.13A). Kinetic parameters produced from the fitting includes rates of 
association (ka) and dissociation (kd), the maximum achievable signal of ligand-analyte 
pairs (Rmax), the bulk signal (RI) from the difference of flow buffer and analyte buffer 
used to better fit binding curves, and Chi2 to give the measure of the accuracy of fit.  
Local fittings of binding curves allow for the individual analyte injections to be 
analyzed separately (Figure 5.0.13B).  The same parameters are determined for local 
Figure 5.0.13 Global and Local Fitting of B3347 
A. Global fitting of concentration-dependent B3347 binding to wildtype AcrB. All 
binding curves are fit simultaneously to describe the overall binding model in this case 
it was the Bivalent Analyte model. B. Local fittings of B3347 allowed for individual 
modeling of the binding curves at each of the various concentrations. A more accurate 
fitting of the single curves produces more accurate rates of association and dissociation 
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fits as with global fits.  Modeling the individual injections to the same model as the 
global allow for more accurate measurements of each binding curve. It also allows for 
the distinction of different patterns of binding within the same analyte as concentrations 
are varied.  
We found that the best model, using global and local fittings, for A3299, B3347, 
F5718, J8043, and N13758 was the bivalent analyte (BA) model.  This assumes that 
binding at the first analyte site facilitates binding at the second site, provided the analyte 
and ligand are in close proximity (Equation 5.1). The dissociation rates in bivalent 
analyte models are slower than when there is only a single site of binding because 
dissociation must occur at both substrate binding sites. 
Table 5.0.4 Kinetic Parameters of AcrB-Inhibitor Interactions 
Data were globally fit using the BA model, k-1, k-2, k1 and k2 are microscopic rate 
constants. Equilibrium dissociation constants (KD) were calculated from the ratios of the 





-1) KD (M) Chi 
A3299 2.35E+01 1.77E-02 4.74E-06 1.74E-01 2.76E+01 22.7 
B3347 1.28E+00 2.12E-02 5.07E-07 1.09E-01 3.56E+03 1090 
F5718 5.00E+01 1.41E-02 1.45E-05 2.11E-05 4.10E-04 122000 
J8043 6.34E+02 3.71E-01 1.59E-06 5.55E-03 2.04E+00 9400 
N13758 4.37E+00 8.10E-02 1.32E-06 1.54E-03 2.16E+01 830 
Analysis of B3347 by global and local fitting showed that the rates of 
association was slower, while rates of dissociation were faster, in the individual injects 
than was reported for the global fitting (Table 5.0.4, 5). Chi2 values show that the 
accuracy of measurements of the single injections are better than with the global fitting.   
Equation 5.0.1 Bivalent Analyte Model Reaction Equation 
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Table 5.0.5 Kinetic Parameters of B3347 from Local Fitting 
B3347 was analyzed by fitting the individual binding curves at the different 
concentrations. Kinetic parameters, using the Bivalent Analyte model, showed more 
accurate, yet varied rates than was observed with the global fitting. 
 ka1 (M-1s-1) kd1 (s-1) ka2 (RU-1s-1) kd2 (s-1) Rmax (RU) RI (RU) Chi2 
62.5 µM B3347 18.6 4.00E-02 4.35E-06 6.10E-06 906 82.2 7.03 
125. µM B3347 42.8 4.11E-02 3.89E-05 9.67E-05 254 179 0.998 
250. µM B3347 28.3 4.35E-02 1.10E-05 2.35E-05 354 314 2.49 
 
Unlike the other inhibitors analyzed on the Biacore 3000, L13711 binding to 
AcrB followed the Two-State (TS) model. This model (Equation 5.0.2) suggests that 
upon binding of substrate, the substrate-ligand complex undergoes a conformational 
change to facilitate the binding of a second substrate. The final substrate-ligand 
complex is the most stable conformation, and dissociation of this complex into the 
independent partners requires a dissociation first to the intermediate conformation. 
 Global fitting showed that L13711 binding to AcrB had rates of 19.5 M-1s-1, 
9.37E-02 s-1, 1.41E-02 RU-1, and 1.47E-02 s-1 for ka1, k d1, ka2 and kd2, respectively. This 
yields an equilibrium constant of 5.01E-02 M, meaning that despite the expected 
stability of the substrate-ligand, dissociation is much faster than association of binding 
partners. 
 Taken together, we illustrate that protein immobilization by thiol coupling 
allows for reversible binding of ligand of interest.  We show and confirm the binding of 
more than one substrate to AcrB. While equilibrium constants could not be determined 
for all tested inhibitors, we were able to characterize the binding patterns by their modes 
Equation 5.0.2 Two-State Binding Model Reaction Equation 
 
Equation 5.0.3 Two-State Binding Model Reaction Equation 
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of cooperative binding. We have, amongst these samples of molecules, potential 
inhibitors that can be used in tandem with therapeutics to destruct efflux pump 
functionality.  
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 III. Conclusions 
Transporter proteins of multidrug efflux pumps are a good target for efflux 
pump inhibitors.  Basilea inhibitors showed preferred binding to the transporter protein 
(AcrB) than to the periplasmic adapter protein (AcrA) or the outer membrane channel 
protein (TolC).  Binding interactions were categorized into the Bivalent Analyte and the 
Two-State binding models. Both models indicate a transition state prior to the final, 
stable complex of protein and inhibitor. 
Fluorescence spectroscopy with pyrene proved a lack of interaction of AcrA-
TolC at previously highlighted amino acid positions.  Experiments with TriABC-OpmH 
proved that the bridging model of interactions between membrane fusion proteins and 
the channel protein was not valid. 
Structural analysis of TriABC showed a stable complex in solution.  TriC is an 
RND transporter exhibiting all three domains of the protein family.  Although the 
TriAB structures were not fully resolved, we present an assembled transporter-MFP 
complex that positions the MFP on the pore and OMP docking domain, as previously 
postulated.  In these studies, we prove that non-equivalent roles of the heterodimeric 
MFP pair.  Assembling asymmetrically around the channel protein, one MFP recruits 
and assembles the efflux pump complex while the other stabilized interactions for 
complex functionality.  The recruiter MFP, located in the intraprotomer groove of the 
outer membrane protein, is responsible for the opening of the periplasmic aperture to 
allow expulsion of substrates of varying classes and function.  The stabilizer MFP, 
located in the interprotomer groove, assumes two different conformations in the 
presence and absence of the channel protein.  A loss of function mutation in the α-
117 
helical domain of this dimeric pair does not disrupt the integrity of the efflux complex.  
These studies present new information about the interactions of proteins and offer more 
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